Rebus (RBSH) S-1/A 14 May 14 IPO registration (amended) Financial data

Document_And_Entity_Informatio

Document And Entity Information	3 Months Ended
	Mar. 31, 2014
Document Information [Line Items]	'
Entity Registrant Name	'GENSPERA INC
Entity Central Index Key	'0001421204
Entity Filer Category	'Smaller Reporting Company
Document Type	'S-1
Amendment Flag	'false
Document Period End Date	31-Mar-14

CONDENSED_BALANCE_SHEETS

CONDENSED BALANCE SHEETS (USD $)	Mar. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current assets:	'	'	'
Cash and cash equivalents	$2,576	$3,587	$2,345
Prepaid expenses	147	163	77
Total current assets	2,723	3,750	2,422
Office equipment, net of accumulated depreciation of $18 and $16	15	14	12
Intangible assets, net of accumulated amortization of $98 and $94	114	118	136
Other assets	3	3	3
Total assets	2,855	3,885	2,573
Current liabilities:	'	'	'
Accounts payable	1,366	1,270	728
Accrued expenses	762	1,250	1,292
Warrant derivative - short-term	'	0	1,176
Convertible notes - stockholder	105	105	105
Total current liabilities	2,233	2,625	3,301
Total liabilities	2,233	2,625	3,301
Commitments and contingencies	'	'	'
Stockholders’ equity:	'	'	'
Preferred stock, par value $0.0001 per share; 30,000,000 shares authorized, none issued and outstanding	0	0	0
Common stock, par value $0.0001 per share; 150,000,000 shares authorized, 27,392,100 and 27,252,966 shares issued and outstanding, respectively	3	3	2
Additional paid-in capital	34,944	33,642	26,353
Deficit accumulated during the development-stage	-34,325	-32,385	-27,083
Total stockholders’ equity	622	1,260	-728
Total liabilities and stockholders’ equity	$2,855	$3,885	$2,573

CONDENSED_BALANCE_SHEETS_Paren

CONDENSED BALANCE SHEETS (Parenthetical) (USD $)	Mar. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
In Thousands, except Share data, unless otherwise specified
Office equipment, accumulated depreciation (in dollars)	$18	$16	$10
Intangible assets, accumulated amortization (in dollars)	$98	$94	$77
Preferred stock, par value (in dollars per share)	$0.00	$0.00	$0.00
Preferred stock, shares authorized	30,000,000	30,000,000	30,000,000
Preferred stock, shares issued	0	0	0
Preferred stock, shares outstanding	0	0	0
Common stock, par value (in dollars per share)	$0.00	$0.00	$0.00
Common stock, shares authorized	150,000,000	150,000,000	150,000,000
Common stock, shares issued	27,392,100	27,252,966	22,298,424
Common stock, shares outstanding	27,392,100	27,252,966	22,298,424

CONDENSED_STATEMENTS_OF_OPERAT

CONDENSED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		12 Months Ended		121 Months Ended	124 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Mar. 31, 2014
Operating expenses:	'	'	'	'	'	'
General and administrative	$836	$741	$3,662	$3,953	$15,765	$16,481
Research and development	1,104	790	2,733	2,922	16,712	17,936
Research and development grant received	0	0	0	0	-489	-489
Total operating expenses	1,940	1,531	6,395	6,875	31,988	33,928
Loss from operations	-1,940	-1,531	-6,395	-6,875	-31,988	-33,928
Financing cost	0	0	0	0	-519	-519
Gain (Loss) on change in fair value of warrant derivative liability	0	235	1,096	-50	86	86
Interest (expense) income, net	0	-1	-3	5	36	36
Loss before provision for income taxes	-1,940	-1,297	-5,302	-6,920	-32,385	-34,325
Provision for income taxes	0	0	0	0	0	0
Net loss	($1,940)	($1,297)	($5,302)	($6,920)	($32,385)	($34,325)
Net loss per common share, basic and diluted (in dollars per share)	($0.07)	($0.06)	($0.21)	($0.32)	'	'
Weighted average shares outstanding (in shares)	27,325,378	22,834,538	24,816,481	21,805,211	'	'

STATEMENT_OF_STOCKHOLDERS_EQUI

STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) (USD $)

Total

Common Stock

Additional Paid-in Capital

Common Stock Subscribed

Deficit Accumulated During Development Stage

Founders

Founders

Shares issued for services

Shares issued for services

Shares issued for services

Placement fees

Accrued Consulting Fees

Accrued Consulting Fees

Accrued Consulting Fees

Payment of consulting fees

Payment of consulting fees

Payment of consulting fees

Warrants 1.65

Warrants 1.65

Warrants 1.65

Warrants 2.00

Warrants 2.00

Warrants 2.00

Warrants 1.80

Warrants 1.80

Warrants 1.80

Warrants 1.80

Warrants 1.773

Warrants 1.773

Warrants 1.773

Warrants 2.20

Warrants 2.20

Warrants 2.20

Warrants 1.50

Warrants 1.50

Warrants 1.50

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Common Stock

Additional Paid-in Capital

USD ($)

Common Stock

Additional Paid-in Capital

Common Stock

USD ($)

Common Stock

Additional Paid-in Capital

USD ($)

Common Stock

Additional Paid-in Capital

USD ($)

Common Stock

Additional Paid-in Capital

USD ($)

Common Stock

Additional Paid-in Capital

USD ($)

Common Stock

Additional Paid-in Capital

Common Stock Subscribed

USD ($)

Common Stock

Additional Paid-in Capital

USD ($)

Common Stock

Additional Paid-in Capital

USD ($)

Common Stock

Additional Paid-in Capital

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Balance at Nov. 20, 2003

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance (in shares) at Nov. 20, 2003

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

'

'

'

1,000

-1,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued (in shares)

'

'

'

'

'

6,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contributed services

120,000

'

120,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-125,000

'

'

'

-125,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at Dec. 31, 2003

-5,000

1,000

119,000

'

-125,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance (in shares) at Dec. 31, 2003

'

6,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contributed services

193,000

'

193,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation

24,000

'

24,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-254,000

'

'

'

-254,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at Dec. 31, 2004

-42,000

1,000

336,000

'

-379,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance (in shares) at Dec. 31, 2004

'

6,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contributed services

48,000

'

48,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation

24,000

'

24,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-127,000

'

'

'

-127,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at Dec. 31, 2005

-97,000

1,000

408,000

'

-506,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance (in shares) at Dec. 31, 2005

'

6,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contributed services

144,000

'

144,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation

42,000

'

42,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-245,000

'

'

'

-245,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at Dec. 31, 2006

-156,000

1,000

594,000

'

-751,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance (in shares) at Dec. 31, 2006

'

6,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

650,000

'

650,000

'

'

'

'

367,000

'

367,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued (in shares)

'

1,300,000

'

'

'

'

'

'

735,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of options for cash

3,000

'

3,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of options for cash (in shares)

'

900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contributed services

220,000

'

220,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation

24,000

'

24,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-691,000

'

'

'

-691,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at Dec. 31, 2007

417,000

1,000

1,858,000

'

-1,442,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance (in shares) at Dec. 31, 2007

'

9,035,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

2,320,000

'

2,320,000

'

'

'

'

50,000

'

50,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued (in shares)

'

2,320,000

'

'

'

'

'

'

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of options for cash

500,000

'

500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of options for cash (in shares)

'

1,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contributed services

50,000

'

50,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation

314,000

'

314,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cost of sales of common stock and warrants

-206,000

'

-206,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares issued for accrued interest

16,000

'

16,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares issued for accrued interest (in shares)

'

31,718

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Beneficial conversion feature of convertible debt

20,000

'

20,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-3,326,000

'

'

'

-3,326,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at Dec. 31, 2008

155,000

1,000

4,922,000

'

-4,768,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance (in shares) at Dec. 31, 2008

'

12,486,718

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cumulative effect of change in accounting principle

-734,000

'

-444,000

'

-290,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants issued for extension of debt maturities

52,000

'

52,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock and warrants issued

3,798,000

1,000

3,797,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock and warrants issued (in shares)

'

2,665,354

'

'

'

'

'

'

'

'

53,334

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

104,000

'

104,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued (in shares)

'

86,875

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation

1,531,000

'

1,531,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock and warrants issued upon conversion of note and accrued interest

174,000

'

174,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock and warrants issued upon conversion of note and accrued interest (in shares)

'

174,165

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-5,134,000

'

'

'

-5,134,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at Dec. 31, 2009

-54,000

2,000

10,136,000

'

-10,192,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance (in shares) at Dec. 31, 2009

'

15,466,446

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Reclassification of derivative liability upon exercise of warrants

86,000

'

86,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock and warrants issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

806,000

'

806,000

2,656,000

'

2,656,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock and warrants issued (in shares)

'

'

'

'

'

'

'

'

'

'

43,632

'

'

'

'

'

'

'

533,407

'

'

1,347,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation

1,165,000

'

1,165,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock and warrants subscribed

612,000

'

'

612,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued as payment for patents and license

47,000

'

47,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued as payment for patents and license (in shares)

'

20,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Salaries paid with common stock

100,000

'

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Salaries paid with common stock (in shares)

'

43,479

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of options and warrants

125,000

'

125,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of options and warrants (in shares)

'

150,001

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-4,257,000

'

'

'

-4,257,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at Dec. 31, 2010

1,286,000

2,000

15,121,000

612,000

-14,449,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance (in shares) at Dec. 31, 2010

'

17,604,465

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock and warrants issued

'

'

'

'

'

'

'

'

'

'

'

60,000

'

60,000

533,000

'

533,000

2,250,000

'

2,250,000

'

'

'

3,423,000

'

4,035,000

-612,000

'

'

'

'

'

'

'

'

'

Common stock and warrants issued (in shares)

'

'

'

'

'

'

'

'

'

'

61,498

'

33,334

'

'

152,895

'

'

1,363,622

'

'

'

'

'

2,241,605

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation

1,290,000

'

1,290,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cost of sales of common stock and warrants

-74,000

'

-74,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-5,714,000

'

'

'

-5,714,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at Dec. 31, 2011

3,054,000

2,000

23,215,000

'

-20,163,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance (in shares) at Dec. 31, 2011

'

21,457,419

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Reclassification of derivative liability upon exercise of warrants

608,000

'

608,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock and warrants issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

674,000

'

674,000

'

'

'

'

'

'

'

'

'

'

'

'

'

652,000

'

652,000

'

'

'

Common stock and warrants issued (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

296,366

'

'

'

'

Exercise of options for cash (in shares)

70,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation

513,000

'

513,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of options and warrants

691,000

'

691,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of options and warrants (in shares)

'

544,639

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-6,920,000

'

'

'

-6,920,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at Dec. 31, 2012

-728,000

2,000

26,353,000

'

-27,083,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance (in shares) at Dec. 31, 2012

'

22,298,424

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Reclassification of derivative liability upon exercise of warrants

80,000

'

80,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock and warrants issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,217,000

'

1,217,000

'

'

'

5,000,000

1,000

4,999,000

Common stock and warrants issued (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

757,794

'

'

'

'

'

3,333,356

'

Exercise of options for cash (in shares)

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation

1,254,000

'

1,254,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of options and warrants

404,000

'

404,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of options and warrants (in shares)

'

863,392

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cost of sales of common stock and warrants

-665,000

'

-665,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-5,302,000

'

'

'

-5,302,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at Dec. 31, 2013

1,260,000

3,000

33,642,000

'

-32,385,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance (in shares) at Dec. 31, 2013

'

27,252,966

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Reclassification of derivative liability upon exercise of warrants

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock and warrants issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

233,000

'

233,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock and warrants issued (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

139,134

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

127,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued (in shares)

91,334

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of options for cash (in shares)

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation

1,069,000

'

1,069,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-1,940,000

'

'

'

-1,940,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at Mar. 31, 2014

$622,000

$3,000

$34,944,000

'

($34,325,000)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance (in shares) at Mar. 31, 2014

'

27,392,100

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

STATEMENT_OF_STOCKHOLDERS_EQUI1

STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical) (USD $)	12 Months Ended										1 Months Ended
	Dec. 31, 2009	Dec. 31, 2008	Dec. 31, 2007	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2003
				Warrants 1.65	Warrants 1.65	Warrants 1.80	Warrants 2.00	Warants 1.773	Warrants 2.20	Warrants 1.50	Founders
Sale of common stock, per share	'	'	$0.50	'	'	'	'	'	'	'	$0.00
Issuance Of Common Stock and Warrants Price Per Share	$1.50	$1	'	$1.65	$1.65	$1.80	$2	$1.77	$2.20	$1.50	'

STATEMENTS_OF_CASH_FLOWS

STATEMENTS OF CASH FLOWS (USD $)	3 Months Ended		12 Months Ended		121 Months Ended	124 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Mar. 31, 2014
Cash flows from operating activities:	'	'	'	'	'	'
Net loss	($1,940)	($1,297)	($5,302)	($6,920)	($32,385)	($34,325)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'	'	'	'	'
Depreciation and amortization	6	5	23	21	111	117
Stock-based compensation	339	119	1,254	513	7,335	6,716
Common stock issued for acquisition of license	0	0	0	0	29	29
Warrants issued for financing costs	0	0	0	0	468	468
Change in fair value of derivative liability	0	-235	-1,096	50	-86	-86
Contributed services	0	0	0	0	774	774
Amortization of debt discount	0	0	0	0	21	21
Increase in operating assets:	'	'	'	'	'	'
Prepaid expenses	16	-78	-86	-77	-163	-147
Other assets	0	0	0	-3	-3	-3
Increase in operating liabilities:	'	'	'	'	'	'
Accounts payable and accrued expenses	570	476	500	1,895	3,280	4,808
Cash used in operating activities	-1,009	-1,010	-4,707	-4,521	-20,619	-21,628
Cash flows from investing activities:	'	'	'	'	'	'
Acquisition of office equipment	-2	-1	-8	-7	-31	-33
Acquisition of intangibles	0	0	0	0	-194	-194
Cash used in investing activities	-2	-1	-8	-7	-225	-227
Cash flows from financing activities:	'	'	'	'	'	'
Proceeds from sale of common stock and warrants	0	1,217	6,217	652	23,844	23,844
Proceeds from exercise of warrants	0	95	405	691	1,221	1,221
Cost of common stock and warrants sold	0	-93	-665	0	-739	-739
Proceeds from convertible notes - stockholder	0	0	0	0	155	155
Repayments of convertible notes - stockholder	0	0	0	0	-50	-50
Cash provided by financing activities	0	1,219	5,957	1,343	24,431	24,431
Net increase (decrease) in cash	-1,011	208	1,242	-3,185	3,587	2,576
Cash, beginning of period	3,587	2,345	2,345	5,530	0	0
Cash, end of period	$2,576	$2,553	$3,587	$2,345	$3,587	$2,576

BACKGROUND

BACKGROUND	3 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'	'
Nature of Operations [Text Block]	'	'
	NOTE 1 – BACKGROUND	NOTE 1 – BACKGROUND
	GenSpera, Inc. (“we”, “us”, “our company”, “our”, “GenSpera” or the “Company”) was formed under the laws of the State of Delaware in November 2003, and has its principal office in San Antonio, Texas. We are a development stage pharmaceutical company focused on the discovery and development of prodrug cancer therapeutics for the treatment of solid tumors, including prostate, liver, brain and other cancers. We plan to develop a series of therapies based on our target-activated prodrug technology platform.	GenSpera, Inc. (“we”, “us”, “our company”, “our”, “GenSpera” or the “Company”) was formed under the laws of the State of Delaware in November 2003, and has its principal office in San Antonio, Texas. We are a development stage pharmaceutical company focused on the discovery and development of prodrug cancer therapeutics for the treatment of solid tumors, including prostate, liver, brain and other cancers.   We plan to develop a series of therapies based on our target-activated prodrug technology platform and further test them through Phase I/II clinical trials.
	Our primary focus at the present time is the clinical development of our lead compound, G-202, a novel therapeutic agent with a unique mechanism of action. We have completed a Phase Ia/Ib dose escalation, safety, tolerability and dose refinement study of G-202, in which we treated a total of 44 patients (includes Phase Ia and Ib), including two patients with hepatocellular carcinoma (HCC), or liver cancer, who experienced prolonged stabilization of disease up to eleven months after initiation of treatment. We are conducting a Phase II clinical trial of G-202 in patients with liver cancer, in which seventeen patients have been treated as of April 26, 2014. We are also conducting a Phase II clinical trial in Glioblastoma (a kind of brain cancer), in which four patients have been treated as of April 26, 2014.	Our primary focus at the present time is the clinical development of our lead compound, G-202, a novel therapeutic agent with a unique mechanism of action. We have completed a Phase Ia/Ib dose escalation, safety, tolerability and dose refinement study of G-202, in which we treated a total of 44 patients (includes Phase Ia and Ib), including two patients with hepatocellular carcinoma (HCC), or liver cancer, who experienced prolonged stabilization of disease up to eleven months after initiation of treatment. We are also conducting a Phase II clinical trial of G-202 in patients with liver cancer. This trial is being conducted at multiple sites in the U.S. and requires seventeen evaluable patients for anticipated statistical analyses. As of February 24, 2014, sixteen patients have been treated, of which the majority of the patients treated are considered to be evaluable.

MANAGEMENTS_PLANS_TO_CONTINUE_

MANAGEMENT'S PLANS TO CONTINUE AS A GOING CONCERN	3 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Management Plans to Continue as Going Concern [Abstract]	'	'
Management Plans to Continue as Going Concern Disclosure [Text Block]	'	'
	NOTE 2 – MANAGEMENT’S PLANS TO CONTINUE AS A GOING CONCERN	Note 2 – Management’s Plans to Continue as a Going Concern
	Basis of Presentation	Basis of Presentation
	We have prepared our financial statements on the basis that we will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Certain information and note disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to those rules and regulations, although we believe that the disclosures made are adequate to make the information not misleading. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for fair presentation have been included. We have incurred losses since inception and have a deficit accumulated of $34.3 million as of March 31, 2014. We anticipate incurring additional losses for the foreseeable future and until such time, if ever, that we can generate significant sales from our therapeutic product candidates currently in development or enter into cash flow positive business development transactions.	The opinion of our independent registered accounting firm on our financial statements contains explanatory going concern language. We have prepared our financial statements on the basis that we will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for fair presentation have been included.
	Development Stage Risks	We have incurred losses since inception and have a deficit accumulated during the development stage of $32.4 million as of December 31, 2013. We anticipate incurring additional losses for the foreseeable future and until such time, if ever, that we can generate significant sales of our therapeutic product candidates currently in development or enter into cash flow positive business development transactions.
	We are a development stage entity. To date, we have generated no sales revenues, have incurred losses and expect to incur significant additional losses as we advance G-202 through clinical studies. Consequently, our operations are subject to all the risks inherent in the establishment of a pre-revenue business enterprise as well as those risks associated with a company engaged in research and development of pharmaceutical compounds.	Development Stage Risks
	Our cash and cash equivalents balance at March 31, 2014 was $2.6 million, representing 90% of our total assets. Based upon our current expected level of operating expenditures, we expect to be able to fund our operations for the next six to nine months. We will require additional cash to fund and continue our operations beyond that point. This period could be shortened if there are any unanticipated significant increases in planned spending on development programs or other unforeseen events. We anticipate raising additional funds through collaborative arrangements, public or private sales of debt or equity securities, or some combination thereof. There is no assurance that any such collaborative arrangement will be entered into or that financing will be available when needed to allow us to continue our operations, or if available, on terms acceptable to us.	We are a development stage entity. To date, we have generated no sales revenues, have incurred losses and expect to incur significant additional losses as we proceed with our Phase II clinical studies. Consequently, our operations are subject to all the risks inherent in the establishment of a pre-revenue business enterprise as well as those risks associated with a company engaged in research and development of novel pharmaceutical compounds.
	In the event financing is not obtained, the Company may pursue cost cutting measures as well as explore the sale of selected assets to generate additional funds. If we are required to significantly reduce operating expenses and delay, reduce the scope of, or eliminate development programs, these events could have a material adverse effect on: our business, results of operations, and financial condition. These factors raise significant doubt about our ability to continue as a going concern. The financial statements do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue in existence.	Our cash and cash equivalents balance at December 31, 2013 was $3.6 million, representing 92% of total assets. Based upon our current expected level of operating expenditures, we expect to able to fund operations for the next nine to twelve months from our year end. We will require additional cash to fund and continue operations beyond that point. This period could be shortened if there are any unanticipated significant increases in planned spending on development programs or other unforeseen events. We need to raise additional funds through collaborative arrangements, public or private sales of debt or equity securities, or some combination thereof. There is no assurance that financing will be available to continue our operations or if available, on terms acceptable to us.
		In the event financing is not obtained, the Company could pursue cost cutting measures as well as explore the sale or licensing of selected assets in order to generate additional funds. If we are required to significantly reduce operating expenses and delay, reduce the scope of, or eliminate development programs, these events could have a material adverse effect on our business, future prospects, results of operations and financial condition. These factors raise significant doubt about our ability to continue as a going concern. The financial statements do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue in existence.

SUMMARY_OF_CRITICAL_ACCOUNTING

SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES

3 Months Ended

12 Months Ended

Mar. 31, 2014

Dec. 31, 2013

Accounting Policies [Abstract]

'

'

Significant Accounting Policies [Text Block]

'

'

NOTE 3 – SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES

NOTE 3 –Summary of Critical Accounting Policies and Use of Estimates

Use of estimates

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying disclosures. Actual results may differ from those estimates.

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying disclosures. Significant estimates include the fair value of derivative instruments, stock-based compensation, recognition of clinical trial costs and other accrued liabilities. Actual results may differ from those estimates.

Research and Development

Research and Development

Research and development costs are charged to expense as incurred. Our research and development expenses consist primarily of expenditures for manufacturing, clinical trials, employee compensation and consulting costs and expenses.

Research and development costs are charged to expense as incurred. Our research and development expenses consist primarily of expenditures for toxicology and other studies, manufacturing, clinical trials, compensation and consulting costs.

We incurred research and development expenses of approximately $1.1 million, $0.8 million and $17.9 million for the three months ended March 31, 2014 and 2013, and from November 21, 2003 (inception) through March 31, 2014, respectively.

We incurred research and development expenses of $2.7 million, $2.9 million and $16.7 million for the years ended December 31, 2013 and 2012, and from November 21, 2003 (inception) through December 31, 2013, respectively.

Loss per Share

Cash Equivalents

Basic loss per share is calculated by dividing net loss and net loss attributable to common shareholders by the weighted average number of common shares outstanding for the period. Basic and diluted loss per share are the same, in that any potential common stock equivalents would have the effect of being anti-dilutive in the computation of net loss per share. The following potentially dilutive securities have been excluded from the computations of weighted average shares outstanding as of March 31, 2014 and 2013, as they would be anti-dilutive:

For purposes of the statements of cash flows, we consider all highly liquid debt instruments purchased with a maturity date of three months or less to be cash equivalents. We maintain our cash in bank deposit accounts which, at times, may exceed applicable government mandate insurance limits. We have not experienced any losses in our accounts.

Three months ended March 31,

Concentrations of Credit Risk

2014

2013

Shares underlying options outstanding

8,334,895

6,023,641

Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments with credit quality institutions. At times, such investments may exceed applicable government mandated insurance limits. Cash and cash equivalents were $3.6 million and $2.3 million at December 31, 2013 and 2012, respectively.

Shares underlying warrants outstanding

10,001,591

8,171,088

Shares underlying convertible notes outstanding

263,695

254,873

We currently outsource all manufacturing of our clinical supplies to single source manufactures. We also have a single source supplier for the active ingredient in our prodrug compounds, including G-202. A change in these suppliers could cause a delay in manufacturing and/or clinical trials, which would adversely affect our Company.

18,600,181

14,449,602

Intangible Assets

Fair Value of Financial Instruments

Intangible assets consist of licensed technology, patents, and patent applications (see Note 5). The assets associated with licensed technology are recorded at cost and are being amortized on the straight line basis over their estimated useful lives of twelve to seventeen years.

Our short-term financial instruments, including cash, accounts payable and other liabilities, consist primarily of instruments without extended maturities. We believe that the fair values of our current assets and current liabilities approximate their reported carrying amounts.

Office Equipment

Warrant derivative liability consists of certain of our warrants with anti-dilution provisions. We use the Black-Scholes option-pricing model to value our warrant derivative liability which incorporates our stock price, volatility, U.S. risk-free interest rate, dividend rate, and estimated life.

Office equipment is stated at cost less accumulated depreciation.  Depreciation is calculated on the straight line basis over the estimated useful lives of the assets of three to five years.  Expenditures for repair and maintenance which do not materially extend the useful lives of property and equipment are charged to expense. When property or equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are removed from the respective accounts with the resulting gain or loss reflected in operations. Management periodically reviews the carrying value of its office equipment for impairment.

Fair Value Measurements

Depreciation expense was approximately $6,000 and $4,000 for the years ended December 31, 2013 and 2012, respectively.

Valuation Hierarchy - GAAP establishes a valuation hierarchy for disclosure of the inputs to valuation used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows:

Loss per Share

Level 1:

Quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2:

Quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument.

Basic loss per share is calculated by dividing net loss and net loss attributable to common shareholders by the weighted average number of common shares outstanding for the period. Basic and diluted loss per share are the same, in that any potential common stock equivalents would have the effect of being anti-dilutive in the computation of net loss per share.

Level 3:

Unobservable inputs based on our own assumptions used to measure assets and liabilities at fair value.

The following potentially dilutive securities have been excluded from the computations of weighted average shares outstanding as of December 31, 2013 and 2012, as they would be anti-dilutive:

A financial asset or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. We previously recorded a warrant derivative liability for warrants with non-standard anti-dilution provisions. These warrants were either exercised or expired as of March 31, 2014.

Year Ended December 31,

Stock-Based Compensation

2013

2012

Shares underlying options outstanding

6,050,623

4,674,628

We measure the cost of employee services received in exchange for equity awards based on the grant-date fair value of the awards. All awards under our stock-based compensation programs are accounted for at fair value and that cost is recognized over the period during which an employee is required to provide service in exchange for the award (the vesting period).

Shares underlying warrants outstanding

10,216,597

8,513,984

Shares underlying convertible notes outstanding

261,519

252,698

Compensation expense for options granted to non-employees is determined in accordance with the standard as the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measured. Compensation expense for awards granted to non-employees is re-measured each accounting period.

16,528,739

13,441,310

Determining the appropriate fair value of the stock-based compensation requires the input of subjective assumptions, including the expected life of the stock-based compensation and stock price volatility. We use the Black-Scholes option-pricing model to value our stock option awards which incorporates our stock price, volatility, U.S. risk-free interest rate, dividend rate, and estimated life.

Fair Value of Financial Instruments

Reclassifications

Our short-term financial instruments, including cash, accounts payable and other liabilities, consist primarily of instruments without extended maturities. We believe that the fair values of our current assets and current liabilities approximate their reported carrying amounts.

Certain prior year balances have been reclassified to conform to current year presentation.

Warrant derivative liability consists of certain of our warrants with anti-dilution provisions. The Company uses the Black-Scholes option-pricing model to value its warrant derivative liability which incorporate the Company’s stock price, volatility, U.S. risk-free interest rate, dividend rate, and estimated life.

Recent Accounting Pronouncements

Fair Value Measurements

Recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the AICPA, and the SEC, did not, or are not believed by management, to have a material impact on the Company’s present or future financial statements.

The U.S. GAAP Valuation Hierarchy establishes a valuation hierarchy for disclosure of the inputs to valuation used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on our own assumptions used to measure assets and liabilities at fair value. A financial asset or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement.

The Company previously had recorded a warrant derivative liability for warrants with anti-dilution provisions, which all the respective warrants were either exercised or expired as of December 31, 2013. The table below summarizes the fair values of our financial liabilities as of December 31, 2012 (in thousands):

Fair Value at

December 31,

Fair Value Measurement Using

2012

Level 1

Level 2

Level 3

Warrant derivative liability

$

1,176

$

—

$

—

$

1,176

The reconciliation of the warrant derivative liability measured at fair value on a recurring basis using unobservable inputs (Level 3) is as follows (in thousands):

2013

2012

Balance at beginning of year

$

1,176

$

1,734

Loss (gain) on change in fair value of warrant liability

-1,096

50

Reclassification to equity upon exercise of warrants

-80

-608

Balance at end of year

$

—

$

1,176

Income Taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income and the reversal of deferred tax liabilities during the period in which the related temporary difference becomes deductible.

Stock-Based Compensation

The Company measures the cost of employee services received in exchange for an equity award based on the grant-date fair value of the award. All grants under our stock-based compensation programs are accounted for at fair value and that cost is recognized over the period during which an employee is required to provide service in exchange for the award (the vesting period).

Compensation expense for options granted to non-employees is determined in accordance with the standard as the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measured. Compensation expense for awards granted to non-employees is re-measured each period.

Determining the appropriate fair value of the stock-based compensation requires the input of subjective assumptions, including the expected life of the stock-based payment and stock price volatility.  The Company uses the Black-Scholes option-pricing model to value its stock option awards which incorporate the Company’s stock price, volatility, U.S. risk-free rate, dividend rate, and estimated life.

Recent Accounting Pronouncements

Recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the AICPA, and the SEC, did not, or are not believed by management, to have a material impact on the Company's present or future financial statements.

SUPPLEMENTAL_CASH_FLOW_INFORMA

SUPPLEMENTAL CASH FLOW INFORMATION	3 Months Ended					12 Months Ended
	Mar. 31, 2014					Dec. 31, 2013
Supplemental Cash Flow Information [Abstract]	'					'
Cash Flow, Supplemental Disclosures [Text Block]	'					'
	NOTE 4 – SUPPLEMENTAL CASH FLOW INFORMATION					NOTE 4 – SUPPLEMENTAL CASH FLOW INFORMATION
	The following table contains additional information for the periods reported (in thousands):					The following table contains additional information for the periods reported (in thousands).
		Three months ended March 31,					Year Ended December 31,
		2014		2013			2013		2012
	Non-cash financial activities:					Non-cash financial activities:
	Common stock options issued as payment of accrued compensation	$	962	$	999	Common stock options issued as payment of accrued compensation	$	999	$	674
	Derivative liability reclassified to equity upon exercise of warrants		–		15	Derivative liability reclassified to equity upon exercise of warrants		80		608
	There was no cash paid for interest and income taxes for the three months ended March 31, 2014 and 2013.					There was no cash paid for interest and income taxes for the years ended December 31, 2013 and 2012.

INTELLECTUAL_PROPERTY

INTELLECTUAL PROPERTY	12 Months Ended
	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Goodwill and Intangible Assets Disclosure [Text Block]	'
	NOTE 5 – INTELLECTUAL PROPERTY
	We solely own or have exclusive licenses to all of our patents and patent applications.  Between 2008 and 2011, we entered into license and assignment agreements with Johns Hopkins University (JHU), the University of Copenhagen (UC) and certain co-inventors (Assignee Co-Founders), in which we paid $212,000 in cash and common stock. As a result of these payments and pursuant to the agreements, we acquired worldwide, exclusive, fully paid up rights in know-how, pre-clinical data, development data and certain patent portfolios that relate to, and form the basis of, our technology. Under these agreements, we are not required to make any other future payments, including fees or other reimbursements, milestones, or royalties, to JHU, UC, or the Assignee Co-Founders.
	Amortization expense recorded during the years ended December 31, 2013 and 2012 was approximately $17,000 for both years. Amortization expense is estimated to be approximately $17,000 for each one of the next five fiscal years.

ACCRUED_EXPENSES

ACCRUED EXPENSES	3 Months Ended					12 Months Ended
	Mar. 31, 2014					Dec. 31, 2013
Accrued Liabilities, Current [Abstract]	'					'
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	'					'
	NOTE 5 – ACCRUED EXPENSES					NOTE 6 – ACCRUED EXPENSES
	Accrued expenses consist of the following (in thousands):					Accrued expenses consist of the following (in thousands):
		March 31,		December 31,			December 31,
		2014		2013			2013		2012
	Accrued compensation and benefits	$	318	$	1,040	Accrued compensation and benefits	$	1,040	$	958
	Accrued research and development		190		82	Accrued research and development		82		100
	Accrued other		254		128	Accrued other		128		234
	Total accrued expenses	$	762	$	1,250	Total accrued expenses	$	1,250	$	1,292

CONVERTIBLE_NOTES_PAYABLE

CONVERTIBLE NOTES PAYABLE	3 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Notes Payable Disclosure [Abstract]	'	'
Notes Payable Disclosure [Text Block]	'	'
	NOTE 6 – CONVERTIBLE NOTES PAYABLE	NOTE 7 – CONVERTIBLE NOTES PAYABLE
	We previously entered into convertible notes with our chief executive officer pursuant to which we borrowed an aggregate of $0.2 million, with $0.1 million principal balance outstanding at March 31, 2014. The notes, which bear interest at a rate of 4.2% per annum and matured at various dates through December 6, 2011, are now considered due on demand. As of March 31, 2014, our chief executive officer has not demanded the payment of the outstanding principal and accrued interest. Accrued interest at March 31, 2014 and December 31, 2013 was approximately $27,000 and $26,000, respectively. The notes and accrued interest are convertible, at the option of the holder, into shares of our common stock at a conversion price of $0.50 per share.	We have issued convertible notes to our chief executive officer pursuant to which we borrowed an aggregate of $0.2 million, with $0.1 million principal balance outstanding at December 31, 2013. The notes bear an interest rate of 4.2% and matured at various dates through December 6, 2011. Accrued interest at December 31, 2013 and December 31, 2012 was approximately $26,000 and $21,000, respectively. As of December 31, 2013, our chief executive officer has not demanded the payment of the outstanding principal and accrued interest. Accordingly, we consider these amounts due on demand. The notes and accrued interest are convertible, at the option of the holder, into shares of our common stock at a conversion price of $0.50 per share.

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'	'
Commitments and Contingencies Disclosure [Text Block]	'	'
	NOTE 7 – COMMITMENTS AND CONTINGENCIES	NOTE 8 –COMMITMENTS AND CONTINGENCIES
	Legal Matters	Operating Leases
	On March 12, 2012, GenSpera instituted a declaratory judgment action against Annastasiah Mhaka (“Mhaka”) in the United States District Court for the District of Maryland: GenSpera, Inc. v. Mhaka, Civil Action No. MJG-12-772 (D. Md.). In that complaint, GenSpera, as the licensee of the inventions described and claimed in the U.S. Patent No. 7,468,354 (“the ‘354 patent”) and U.S. Patent No. 7,767,648 (“the ‘648 patent”), sought a declaratory judgment that Mhaka (a former doctoral student at Johns Hopkins University) should not be added to either the ‘354 patent or the ‘648 patent as an inventor. On April 2, 2012, Mhaka filed and served her answer and counterclaim, in which she sought to be added as an inventor to the ‘354 patent and the ‘648 patent pursuant to 35 U.S.C. sec. 256. Between April 26, 2012 and October 1, 2012, the parties conducted fact discovery. Between October 1, 2012 and December 1, 2012, the parties conducted limited expert discovery. On November 1, 2012, Mhaka filed a separate complaint in the State Circuit Court for Baltimore County, Maryland, naming GenSpera as a defendant along with Dr. Samuel Denmeade and Dr. John Isaacs (the named inventors on the ‘354 patent and the ‘648 patent). In the complaint, Mhaka alleged that the defendants are liable under various state law tort theories for the same alleged conduct that formed the basis for her prior inventorship claim. In her prayer for relief, Mhaka sought unspecified damages from the defendants but did not seek to alter the inventorship or ownership of the ‘354 patent or ‘648 patent. On November 8, 2012, the defendants removed this second action to the United States District Court for the District of Maryland, and on November 16, 2012, the defendants moved to dismiss all claims in the complaint, asserting (among other things) that the claims were preempted by federal patent law.	The Company leases its corporate offices under an operating lease that expires on October 14, 2015.  Rent expense for office space amounted to approximately $55,000 and $26,000 for the years ended December 31, 2013 and 2012, respectively. The following table summarizes future minimum lease payments as of December 31, 2013 (in thousands):
	On January 24, 2013, the Court heard GenSpera’s motion for summary judgment in the original case and the defendants’ motion to dismiss in the second case. On May 1, 2013, the Court granted GenSpera’s motion for summary judgment in the original case. In its order, the Court stated that it would proceed to issue a declaratory judgment establishing that Mhaka should not be added to the two patents at issue as an additional inventor pursuant to 35 U.S.C. § 256. Reserving any ruling on the issue of whether Mhaka’s state law tort claims are preempted by federal patent law, the Court denied defendants’ motion to dismiss Mhaka’s complaint and directed Mhaka to re-file her claims as counterclaims in the original action. On May 14, 2013, Mhaka filed an amended answer and counterclaims in the consolidated action, re-pleading her tort claims as counterclaims. On June 3, 2013, GenSpera (along with Drs. Denmeade and Isaacs) filed a reply to the counterclaims, denying their allegations and raising a number of affirmative defenses. Fact discovery was completed on December 13, 2013, and expert discovery was completed on March 28, 2014. On January 2, 2014, Drs. Isaacs and Denmeade moved for summary judgment on the grounds that Mhaka’s claims are barred by the applicable statute of limitations, and GenSpera joined in the motion. The briefing on that motion is now complete. GenSpera filed a separate motion for summary judgment on May 6, 2014. Mhaka’s opposition to that motion is due to be filed on or before May 28, 2014. GenSpera’s reply brief in support of the motion is due on June 4, 2014. Further scheduling, as appropriate, is to be set after resolution of summary judgment motions.	2014	$	56
		2015		45
		Thereafter		–
		Total minimum lease payments	$	101
		Employment Agreements
		We employ our Chief Executive Officer and Chief Operating Officer pursuant to written employment agreements. The employment agreements contain severance provisions and indemnification clauses.  The indemnification agreement provides for the indemnification and defense of the executive officers, in the event of litigation, to the fullest extent permitted by law. As part of the agreements, the executives potentially shall be entitled to the following (in thousands):
			Chief		Chief
			Executive		Operating
			Officer		Officer
		Terminated without cause	$	1,727	$	909
		Terminated, change of control without good reason		1,727		—
		Terminated for cause, death, disability and by executive without good reason		363		309
		Legal Matters
		On March 12, 2012, GenSpera instituted a declaratory judgment action against Annastasiah Mhaka (“Mhaka”) in the United States District Court for the District of Maryland: GenSpera, Inc. v. Mhaka, Civil Action No. MJG-12-772 (D. Md.). In that complaint, GenSpera, as the licensee of the inventions described and claimed in the U.S. Patent No. 7,468,354 (“the ‘354 patent”) and U.S. Patent No. 7,767,648 (“the ‘648 patent”), sought a declaratory judgment that Mhaka (a former doctoral student at Johns Hopkins University) should not be added to either the ‘354 patent or the ‘648 patent as an inventor.   On April 2, 2012, Mhaka filed and served her answer and counterclaim, in which she sought to be added as an inventor to the ‘354 patent and the ‘648 patent pursuant to 35 U.S.C. sec. 256. Between April 26, 2012 and October 1, 2012, the parties conducted fact discovery. Between October 1, 2012 and December 1, 2012, the parties conducted limited expert discovery. On November 1, 2012, Mhaka filed a separate complaint in the State Circuit Court for Baltimore County, Maryland, naming GenSpera as a defendant along with Dr. Samuel Denmeade and Dr. John Isaacs (the named inventors on the ‘354 patent and the ‘648 patent). In the complaint, Mhaka alleged that the defendants are liable under various state law tort theories for the same alleged conduct that formed the basis for her prior inventorship claim. In her prayer for relief, Mhaka sought unspecified damages from the defendants but did not seek to alter the inventorship or ownership of the ‘354 patent or ‘648 patent. On November 8, 2012, the defendants removed this second action to the United States District Court for the District of Maryland, and on November 16, 2012, the defendants moved to dismiss all claims in the complaint, asserting (among other things) that the claims were preempted by federal patent law.
		On January 24, 2013, the Court heard GenSpera’s motion for summary judgment in the original case and the defendants’ motion to dismiss in the second case. On May 1, 2013, the Court granted GenSpera’s motion for summary judgment in the original case. In its order, the Court stated that it would proceed to issue a declaratory judgment establishing that Mhaka should not be added to the two patents at issue as an additional inventor pursuant to 35 U.S.C. § 256. Reserving any ruling on the issue of whether Mhaka’s state law tort claims are preempted by federal patent law, the Court denied defendants’ motion to dismiss Mhaka’s complaint and directed Mhaka to re-file her claims as counterclaims in the original action.  On May 14, 2013, Mhaka filed an amended answer and counterclaims in the consolidated action, re-pleading her tort claims as counterclaims. On June 3, 2013, GenSpera (along with Drs. Denmeade and Isaacs) filed a reply to the counterclaims, denying their allegations and raising a number of affirmative defenses. Fact discovery was completed on December 13, 2013, and expert discovery is to be completed by February 28, 2014.  On January 2, 2014, Drs. Isaacs and Denmeade moved for summary judgment on the grounds that Mhaka’s claims are barred by the applicable statute of limitations, and GenSpera joined in the motion. The briefing on that motion is now complete.  Any remaining motions for summary judgment are to be filed by April 15, 2014. Further scheduling, as appropriate, is to be set after resolution of summary judgment motions.

CAPITAL_STOCK_AND_STOCKHOLDERS

CAPITAL STOCK AND STOCKHOLDER'S EQUITY	3 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Stockholders' Equity Note [Abstract]	'	'
Stockholders' Equity Note Disclosure [Text Block]	'	'
	NOTE 8 – CAPITAL STOCK AND STOCKHOLDER’S EQUITY	NOTE 9 – CAPITAL STOCK AND STOCKHOLDER’S EQUITY
	Common Stock	Common Stock
	In February 2014, we entered into an agreement with H.C. Wainwright to serve as our exclusive placement agent, advisor and underwriter for a proposed offering of our securities. We agreed to pay the placement agent a placement fee equal to 8% of the aggregate gross proceeds received by us from our sale of the securities in the offering and to issue the placement agent warrants to purchase shares of common stock equal to 8% of the common stock sold to investors.	During the year ended December 31, 2013, 325,670 warrants were exercised into an equivalent number of common shares for which we received proceeds of approximately $404,000, and one million warrants were exercised on a cashless basis into 537,722 common shares.
	In February 2014, we entered into an agreement for method development by a contract manufacturer and issued an aggregate of 91,334 shares of common stock, valued at approximately $127,000, as compensation. In February 2014, we entered into an agreement to grant an aggregate of 47,800 shares of common stock, valued at approximately $67,000, to a consultant for business advisory services to be provided to the Company.	During the year ended December 31, 2012, 544,639 options and warrants were exercised into an equivalent number of common shares. We received proceeds of $691,000 from the exercise of the options and warrants, and 78,333 warrants were exercised on a cashless basis into 37,301 common shares.
	During the three months ended March 31, 2014, no warrants were exercised into common shares. During the three months ended March 31, 2013, 119,100 warrants were exercised into an equivalent number of common shares for which we received proceeds of approximately $95,000 and one million warrants were exercised on a cashless basis into 537,722 common shares.	Equity Financing
		August 2013 Offering
		In August of 2013, we sold an aggregate of $5,000,032, or 3,333,356 units, to accredited and institutional investors. The price per unit was $1.50, with each unit consisting of (i) one share of the Company’s common stock and (ii) one common stock purchase warrant. The warrants have a term of five years and entitle the holder to purchase the Company’s common stock at a price per share of $1.75. In the event that the shares underlying the warrants are not subject to a registration statement at the time of exercise, the warrants may be exercised on a cashless basis after 6 months from the issuance date. The warrants also contain provisions providing for an adjustment in the underlying number of shares and exercise price in the event of stock splits or dividends and fundamental transactions. Additionally, the warrants contain limitations on the holder’s ability to exercise the warrants in the event such exercise causes the holder to beneficially own in excess of 4.99% of the Company’s issued and outstanding common stock, subject to a discretionary increase in such limitation by the holder to 9.99% upon 61 days’ prior notice to the Company.
		In connection with the offering, we also paid commissions equal to 8% of gross proceeds, for an aggregate commission of $400,003, and a non-accountable expense allowance equal to 2% of the gross proceeds, or $100,001 to the placement agent. The placement agent also received common stock purchase warrants to purchase such number of shares equal to 8% of the shares sold in the offering to investors, or 266,668 placement agent warrants with substantially the same terms as the warrants. Additionally, the placement agent was also reimbursed for its legal and due diligence costs in an amount not greater than $35,000. The placement agent will also receive (i) a cash fee of 4% of gross proceeds received from the exercise of the warrants, and (ii) additional transaction fees equal to 8% of gross proceeds and 8% warrant coverage for any future investment by one of the investors in the Company for a period of 12 months following the closing of the offering.
		In connection with the offering, investors received certain registration rights. Pursuant to the registration rights, the Company agreed to file a registration statement with the SEC within 45 days from the closing to register the resale of the common shares and common shares underlying the warrants. The Company also agreed to have the registration statement declared effective within 120 days from the filing date. The Company agreed to keep the registration statement continuously effective until the earlier to occur of (i) the date after which all of the securities to be registered thereunder have been sold, or (ii) the date on which all the securities to be registered thereunder may be sold without volume or manner-of-sale restrictions and without current public information pursuant to Rule 144 under the Securities Act of 1933, as amended. We are also obligated to pay the investors, as partial liquidated damages, a fee of 1.5% of each investor’s subscription amount per month in cash or shares of the Company’s common stock, at the discretion of the Company, upon the occurrence of certain events, including our failure to file and / or failure to have the registration statement declared effective within the time provided. The Company has satisfied the filing deadline and effectiveness condition.
		December 2012 Offering
		In December of 2012 we commenced a unit offering of our securities.  Each unit consists of: (i) one share of common stock, and (ii) one common stock purchase warrant. The warrants have a term of five years and entitle the holders to purchase common stock at a price per share of $3.00. In the event the shares underlying the warrants are not subject to a registration statement, the warrants may be exercised on a cashless basis after 12 months from the issuance date. The warrants also contain provisions providing for an adjustment in the underlying number of shares and exercise price in the event of stock splits or dividends and fundamental transactions, as defined. The warrants do not contain any price protection provisions. Additionally, the warrants contain limitations on the holder’s ability to exercise the warrants in the event such exercise causes the holder to beneficially own in excess of 4.99% of the Company’s issued and outstanding common stock, subject to a discretionary increase in such limitation by the holder to 9.99% upon 61 days’ prior notice to the Company.
		In January 2013, we offered and sold an aggregate of 104,095 units in an additional closing resulting in gross proceeds of $0.2 million. The price per unit was $2.20. In connection with the December 2012 and January 2013 closings, we issued 96,443 additional units in March 2013 in order to adjust the price per unit from $2.20 to $1.773 to be consistent with the price per unit of our March 2013 closing as discussed below.
		In March 2013, we offered and sold an additional 557,256 units in connection with an additional closing, resulting in gross proceeds of $1.0 million, at a price per unit of $1.773. In connection with this closing, we incurred placement agent fees and expenses in the amount of $37,000 in cash and issued warrants to purchase 18,410 shares at an exercise price per share of $3.00.
		In connection with the offering, we agreed to enter into registration rights agreements with our investors. Pursuant to the registration rights agreements, we agreed to file a “resale” registration statement with the SEC covering the shares of common stock included in the units as well as the shares underlying the warrants, within 45 days of the final closing date of the sale of units and to maintain the effectiveness of the registration statement until all securities have been sold or are otherwise able to be sold pursuant to Rule 144. We also agreed to use our best efforts to have the registration statement declared effective within 90 days of the final closing. We are also obligated to pay to investors, as partial liquidated damages, a fee of 0.50% per month in cash up to a maximum of 6%, upon the occurrence of certain events, including but not limited to failure to file and/or have the registration statement declared effective within the time provided. Subsequent to the offering, we received a waiver and amendment to the registration rights agreement by holders of a majority of the registrable securities. The effect of the waiver and amendment was to waive all penalties under the registration rights agreement with regard to filing deadlines and effectiveness requirements.

STOCK_OPTIONS

STOCK OPTIONS	3 Months Ended								12 Months Ended
	Mar. 31, 2014								Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'								'
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	'								'
	NOTE 9 – STOCK OPTIONS								NOTE 10 – STOCK OPTIONS
	The terms of our 2009 Executive Compensation Plan (“2009 Plan”) and our 2007 Equity Compensation Plan (“2007 Plan”) allow for the issuance of up to 6,000,000 shares of common stock each. Collectively, the 2009 Plan and 2007 Plan are referred to as “the Plans.” Total stock-based compensation expense recognized for stock options and warrants issued using the straight-line method in the statement of operations for the three months ended March 31, 2014 and 2013 was $1,069,000 and $1,077,000, respectively, of which $962,000 and $958,000 was accrued as of December 31, 2013 and 2012, respectively.								Deferred Compensation Plan
	The following table summarizes stock option activity under the Plans:								In July of 2011, we adopted Executive Deferred Compensation Plan (the Deferred Plan). The Deferred Plan is intended to comply with the requirements of Section 409A of the Internal Revenue Code of 1986, as amended (the Code). The Deferred Plan is intended to be an unfunded “top hat” plan which is maintained primarily to provide deferred compensation benefits for a select group of our “management or highly compensated employees” within the meaning of Sections 201, 301, and 401 of the Employee Retirement Income Security Act of 1974, as amended (ERISA), and to therefore be exempt from the provisions of Parts 2, 3, and 4 of Title I of ERISA. The Deferred Plan is intended to help build a supplemental source of savings and retirement income through pre-tax deferrals of eligible compensation, which may include cash, option and stock bonus awards, discretionary cash, option and stock awards and/or any other payments which may be designated by the Deferred Plan administrator, as eligible, for deferral under the Deferred Plan from time to time. As administered, the Deferred Plan is used to defer compensation of stock awards granted under our other equity compensation plans and does not by its terms approve any grants or awards.
		Number of		Weighted-		Weighted-average	Aggregate		GenSpera’s Compensation Plans
		shares		Average		Remaining	Intrinsic
				Exercise		contractual term	value (in		The Company’s 2007 Equity Compensation Plan (2007 Plan) and 2009 Executive Compensation Plan (2009 Plan) (together, the Plans) provide for the awarding of stock grants, nonqualified and incentive stock options, restricted stock units, performance units or other stock-based awards to officers, directors, employees and consultants of the Company. The purpose of the Plans is to advance the interests of GenSpera and our stockholders by attracting, retaining and rewarding persons performing services for us and to motivate such persons to contribute to our growth and profitability. Our Plans are administered by a committee of non-employee directors (the Committee). The Committee determines: who shall be granted awards; the vesting periods; the exercise price; and any other terms deemed appropriate for any award.
				price		(in years)	thousands)
	Outstanding at December 31, 2013	6,050,623		$	1.82				As of December 31, 2013, our 2009 Plan authorized up to 6,000,000 shares of common stock to be reserved for issuance upon exercise of stock options or other stock-based awards, and the Company has awarded 2,996,972 stock options, and 3,003,028 shares of common stock were available for future grants under the 2009 Plan. All option awards granted under the 2009 Plan are fully vested.
	Granted	2,284,272		$	1.36
	Exercised	—			—				Our 2007 Plan authorizes up to 6,000,000 shares of common stock to be reserved for the issuance upon exercise of stock options or other stock-based awards, subject to an annual award limitation of 1,500,000 shares. Under the 2007 Plan, vesting schedules for stock options vary, but generally vest for a period of not more than five years and at a rate of not less than 20% per year. The maximum term of an option granted under the 2007 Plan is ten years. As of December 31, 2013, the Company has awarded 3,363,651 stock options, and 2,776,349 shares of common stock were available for future grants under the 2007 Plan.
	Forfeited	—			—
	Outstanding at March 31, 2014	8,334,895		$	1.7	4.5	$	283	Total stock-based compensation expense recognized for stock options issued using the straight-line method in the statement of losses for the year ended December 31, 2013 and 2012 is as follows (in thousands):
	Exercisable at March 31, 2014	8,132,015		$	1.7	4.5	$	280		2013			2012
									Stock-based compensation expense for employees and non-employee directors	$	1,140		$	322
	As of March 31, 2014, there was $0.1 million of total unrecognized compensation cost related to non-vested stock options which vest over time. That cost is expected to be recognized over a weighted-average period of approximately one year. As of March 31, 2014, there was no unrecognized compensation expense related to performance-based, non-vested employee stock options.								Equity awards for nonemployees issued for services		114			191
									Total stock-based compensation expense	$	1,254		$	513
	During the three months ended March 31, 2014, we issued options to purchase 1,948,902 and 38,000 shares of common stock to employees and non-employee directors, respectively, under the Plans. Additionally, we issued options to purchase 297,370 shares of common stock to consultants. During the three months ended March 31, 2013, we issued options to purchase 1,221,972 and 38,000 shares of common stock to employees and non-employee directors, respectively, under the Plans. Additionally, we issued options to purchase 89,041 shares of common stock to consultants. During the three months ended March 31, 2014 and 2013, no options were exercised.
									The following table summarizes stock option activity under the Plans:
	The following table summarizes weighted-average assumptions using the Black-Scholes option-pricing model used on the date of the grants issued during the three months ended March 31, 2014 and 2013:
		Three months ended March 31,													Weighted-
		2014		2013								Weighted-			average	Aggregate
	Volatility	56	%	59.1	%							average			remaining	intrinsic
	Expected term (years)	3.4		3.6						Number of		exercise			contractual term	value (in
	Risk-free interest rate	0.5	%	0.5	%					shares		price			(in years)	thousands)
	Dividend yield	0	%	0	%				Outstanding at December 31, 2011	3,646,870		$	1.6
									Granted	1,097,758		$	2.33
									Exercised	-70,000		$	0.5
									Forfeited	—			—
									Outstanding at December 31, 2012	4,674,628		$	1.79
									Granted	1,515,995		$	2.02
									Exercised	–		$	–
									Forfeited	-140,000		$	2.8
									Outstanding at December 31, 2013	6,050,623		$	1.82		4	$	272
									Exercisable at December 31, 2013	5,952,726		$	1.83		4	$	269
									As of December 31, 2013, there was $0.1 million of total unrecognized compensation cost related to non-vested stock options which vest over time.  That cost is expected to be recognized over a weighted-average period of 0.5 years. As of December 31, 2013, there was no unrecognized compensation expense related to performance-based, non-vested employee stock options.
									During 2013 and 2012, the Company issued options to purchase 1,335,972 and 1,094,658 shares of common stock, respectively, to employees, and non-employee directors under the Plans.  The per share weighted-average fair value of the options granted to employees and non-employee directors during 2013 and 2012 was estimated at $0.84 and $0.99, respectively, on the date of grant.
									During 2013 and 2012, the Company issued options to purchase 180,023 and 3,100 shares of common stock, respectively, to consultants under the Plan. The per-share weighted-average fair value of the options granted to consultants during 2013 and 2012 was estimated at $0.75 and $1.27, respectively, on the date of grant.
									The following table summarizes weighted-average assumptions using the Black-Scholes option-pricing model used on the date of the grants issued for the years ended December 31, 2013 and 2012:
										Year Ended December 31,
										2013		2012
									Volatility	58.8	%	71.9	%
									Expected term (years)	3.7		2.8
									Risk-free interest rate	0.6	%	0.3	%
									Dividend yield	None		None
									No options were exercised during the year ended December 31, 2013.  During the year ended December 31, 2012, 70,000 options were exercised into an equivalent number of common shares. We received proceeds of $35,000 from the exercise of the options.

WARRANTS_AND_DERIVATIVE_WARRAN

WARRANTS AND DERIVATIVE WARRANT LIABILITY	3 Months Ended								12 Months Ended
	Mar. 31, 2014								Dec. 31, 2013
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'								'
Derivatives and Fair Value [Text Block]	'								'
	NOTE 10 – WARRANTS AND DERIVATIVE WARRANT LIABILITY								NOTE 11 –WARRANTS AND DERIVATIVE WARRANT LIABILITY
	We account for common stock purchase warrants as either equity instruments or derivative liabilities depending on the specific terms of the warrant agreement. Warrants are accounted for as derivative liabilities if the warrants allow for cash settlement or provide for modification of the warrant exercise price in the event subsequent sales of common stock by the Company are at a lower price per share than the then-current warrant exercise price. We classify derivative warrant liabilities on the balance sheet at fair value, and changes in fair value during the periods presented in the statement of operations, which is revalued at each balance sheet date subsequent to the initial issuance of the warrant. At March 31, 2014, all outstanding liability-classified warrants were either exercised or had expired.								We account for common stock warrants as either equity instruments or derivative liabilities depending on the specific terms of the warrant agreement.  Common stock warrants are accounted for as derivative liabilities if the stock warrants allow for cash settlement or provide for modification of the warrant exercise price in the event subsequent sales of common stock are at a lower price per share than the then-current warrant exercise price.  We classify derivative warrant liabilities on the balance sheet at fair value, and changes in fair value during the periods presented in the statement of operations, which is revalued at each balance sheet date subsequent to the initial issuance of the stock warrant.  Transactions involving our equity-classified and liability-classified stock warrants are summarized as follows:
	Transactions involving our equity-classified warrants are summarized as follows:													Weighted-
												Weighted-		average	Aggregate
		Number of		Weighted-		Weighted-average	Aggregate					average		remaining	intrinsic
		shares		Average		Remaining	Intrinsic			Number of		exercise		contractual term	value (in
				Exercise		contractual term	value (in			shares		price		(in years)	thousands)
				price		(in years)	thousands)
	Outstanding at December 31, 2013	10,216,597		$	2.56				Outstanding at December 31, 2011	8,715,289		$	2.39
	Granted	96,000		$	3				Granted	314,366		$	2.97
	Exercised	—			—				Exercised	-515,671		$	1.52
	Forfeited	-311,006		$	2.71				Forfeited	—			—
	Outstanding at March 31, 2014	10,001,591		$	2.56	2.8	$	48
									Outstanding at December 31, 2012	8,513,984		$	2.47
	Exercisable at March 31, 2014	10,001,591		$	2.56	2.8	$	48	Granted	4,376,228		$	1.97
									Exercised	-1,325,670		$	1.06
	During the three months ended March 31, 2014, no warrants were exercised. During the three months ended March 31, 2013, 119,100 warrants were exercised into an equivalent number of common shares and 1,000,000 warrants were exercised on a cashless basis into 537,722 common shares.								Forfeited	-1,347,945		$	1.52
									Outstanding at December 31, 2013	10,216,597		$	2.56	2.9	$	48
	The following table summarizes outstanding common stock purchase warrants as of March 31, 2014:
									Exercisable at December 31, 2013	10,216,597		$	2.56	2.9	$	48
		Number of		Weighted-		Expiration
		shares		average					During the year ended December 31, 2013, 325,670 warrants were exercised into an equivalent number of common shares for which we received approximately $404,000 in proceeds, and 1,000,000 warrants were exercised on a cashless basis into 537,722 common shares. During the year ended December 31, 2012, 515,671 warrants were exercised into an equivalent number of common shares. We received proceeds of $0.7 million from the exercise of the options.
				exercise
				price					The following table summarizes outstanding warrants to purchase common stock as of December 31, 2013:
	Equity–classified warrants
	Issued to consultants	1,163,759		$	2.36	July 2014 through February 2019						Weighted
	Issued pursuant to 2009 financings	1,205,510		$	3	June 2014 through September 2014						Average
	Issued pursuant to 2010 financings	1,022,943		$	3.38	January 2015 through May 2015				Number of		Exercise
	Issued pursuant to 2011 financings	1,936,785		$	3.24	January 2016 through April 2016				shares		price		Expiration
	Issued pursuant to 2012 financings	296,366		$	3	Dec-17			Equity–classified warrants
	Issued pursuant to 2013 financings	4,376,228		$	1.97	December 2017 through August 2023			Issued to consultants	1,128,759		$	2.28	February 2014 through January 2018
		10,001,591							Issued pursuant to 2009 financings	1,455,516		$	3	February 2014 through September 2014
									Issued pursuant to 2010 financings	1,022,943		$	3.38	January 2015 through May 2015
	Equity-classified Warrants								Issued pursuant to 2011 financings	1,936,785		$	3.24	January 2016 through April 2016
									Issued pursuant to 2012 financings	296,366		$	3	Dec-17
	During the three months ended March 31, 2014, we issued warrants to consultants to purchase 96,000 shares of common stock. The per share weighted-average fair value of the warrants granted to consultants during 2014 was estimated at $0.41 per share on the date of grant. During the three months ended March 31, 2013, no warrants were issued to consultants. Total stock-based compensation expense of approximately $40,000 and $4,000 was recognized for warrants and included in the statement of operations for the three months ended March 31, 2014 and 2013, respectively.								Issued pursuant to 2013 financings	4,376,228		$	1.97	December 2017 through August 2023
										10,216,597
	During the three months ended March 31, 2013, in connection with the offering of our securities, we issued an aggregate of 776,204 common stock purchase warrants, including: 686,420 pursuant to closings in January 2013 and March 2013; 18,410 to the placement agent; and 71,374 additional warrants issued to investors that participated in the December 2012 closing. All warrants were issued with an exercise price of $3.00 per share.
									Equity-classified Warrants
	Liability-classified Warrants
									During 2013, the Company did not issue any warrants to consultants to purchase shares of common stock. During 2012, the Company issued warrants to consultants to purchase 18,000 at a weighted-average fair value of $1.31 per share on the date of grant. Total stock-based compensation expense recognized for warrants issued to consultants using the straight-line method in the statement of losses for the year ended December 31, 2013 and 2012 was $2,000 and $14,000, respectively.
	We have assessed our outstanding equity-linked financial instruments and have concluded that certain of our warrants are subject to derivative accounting as a result of certain non-standard anti-dilution provisions contained in the warrants. The fair value of these warrants is classified as a liability in the financial statements with the change in fair value during the periods presented, recorded in the statement of operations. At March 31, 2014, all outstanding liability-classified warrants were either exercised or had expired.
									The following table summarizes weighted-average assumptions using the Black-Scholes option-pricing model used on the date of the equity-classified warrants issued for services for the year ended December 31, 2012:
	We did not record a gain or loss during the three months ended March 31, 2014, as the outstanding liability-classified warrants were either exercised or had expired. We recorded a gain of $0.2 million during the three months ended March 31, 2013, related to the change in fair value of the warrant derivative liability during that period. The following table summarizes the calculated aggregate fair values for the warrant derivative liability using the Black-Scholes method based on the following assumptions:
									Volatility	60.3	%
		Fair value as of							Expected term (years)	4.7
		March 31, 2013							Risk-free interest rate	0.7	%
									Dividend yield	None
	Calculated aggregate value (in thousands)	$	1,010
	Exercise price per share of warrant	$	1.5
	Closing price per share of common stock	$	2.15						During the first three months of 2013, in connection with multiple closings of the December 2012 offering, the Company issued an aggregate of 776,204 common stock purchase warrants, including: 686,420 pursuant to closings in January 2013 and March 2013; 18,410 to the placement agent; and 71,374 additional warrants issued to investors that participated in the December 2012 closing. All warrants were issued with an exercise price of $ 3.00 per share. In connection with our August 2013 offering, the Company issued an aggregate of 3,600,024 common stock purchase warrants, including: 3,333,356 issued to investors, and 266,668 to the placement agents. All warrants were issued with an exercise price of $ 1.75 per share. During the first three months of 2013, in connection with multiple closings of the December 2012 offering, the Company issued an aggregate of 776,204 common stock purchase warrants, including: 686,420 pursuant to closings in January 2013 and March 2013; 18,410 to the placement agent; and 71,374 additional warrants issued to investors that participated in the December 2012 closing. All warrants were issued with an exercise price of $ 3.00 per share. In connection with our August 2013 offering, the Company issued an aggregate of 3,600,024 common stock purchase warrants, including: 3,333,356 issued to investors, and 266,668 to the placement agents. All warrants were issued with an exercise price of $ 1.75 per share.
	Volatility		50	%
	Expected term (years)		0.3						Liability-classified Warrants
	Risk-free interest rate		0.07	%
	Dividend yield		0	%					The Company has assessed its outstanding equity-linked financial instruments and has concluded that certain of its common stock purchase warrants are subject to derivative accounting, as a result of certain anti-dilution provisions contained in the warrants. The fair value of these warrants was classified as a liability in the financial statements with the change in fair value during the periods presented recorded in the statement of operations. At December 31, 2013, all outstanding liability-classified warrants were either exercised or had expired.
									The following table summarizes the calculated aggregate fair values for the warrant derivative liability using the Black-Scholes method based on the following assumptions (in thousands):
										Fair value as of
										December 31,
										2012
									Calculated aggregate value	$	1,176
									Exercise price per share of warrant	$	1.5
									Closing price per share of common stock	$	2.2
									Volatility		54	%
								Expected term (years)		0.5
								Risk-free interest rate		0.11	%
								Dividend yield		0	%
								We have recorded a gain of $1.1 million and a loss of $1.0 million during the year ended December 31, 2013 and 2012, respectively, related to the change in fair value of the warrant derivative liability during that period, and for the expiration of such warrants during the year. In addition, we reclassified approximately $80,000 and $608,000 of the derivative liability as a result of approximately 242,000 and 437,000 warrants being exercised in 2013 and 2012, respectively.

INCOME_TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income Tax Disclosure [Text Block]	'
	NOTE 12 – INCOME TAXES
	The Company had, subject to limitation, $22.0 million of net operating loss carryforwards at December 31, 2013, which will expire at various dates beginning in 2013 through 2024. In addition, the Company has research and development tax credits of approximately $398,000 at December 31, 2013 available to offset future taxable income, which will expire from 2028 through 2034. We have provided a 100% valuation allowance for the deferred tax benefits resulting from the net operating loss carryover and our tax credits due to our lack of earnings history. In addressing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences are deductible. The valuation allowance increased by $1.7 and $1.8 million for the years ended December 31, 2013 and 2012, respectively.
	Significant components of deferred tax assets and liabilities are as follows (in thousands):
		2013			2012
	Deferred tax assets:
	Net operating loss carryover	$	7,497		$	5,793
	Stock-based compensation		2,888			2,474
	Other		19			339
	Tax credits		398			374
	Total deferred tax assets		10,802			8,980
	Less: valuation allowance		-10,802			-8,980
	Net deferred tax assets	$	–		$	–
	The actual tax benefit differs from the expected tax benefit for the years ended December 31, 2013 and 2012 (computed by applying the U.S. Federal Corporate tax rate of 34% to income before taxes) are as follows:
		2013		2012
	Statutory federal income tax rate	-34	%	-34	%
	Non-deductible items	0.1	%	0	%
	Adjustment for R&D Credit	-0.4	%	-0.8	%
	Valuation allowance	34.4	%	34.8	%
	Effective income tax rate	–	%	–	%
	The Company’s tax returns for the previous three years remain open for audit by the respective tax jurisdictions.

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2013
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	NOTE 13 – SUBSEQUENT EVENTS
	In January 2014, we issued options to purchase an aggregate of 1,948,902 shares of common stock to executive management in connection with their annual bonus and 2013 long term incentive plan. The options have a term of seven years, an exercise price of between $1.29 and $1.42, and are fully vested on the grant date. The Company recorded $962,000 in stock-based compensation expense related to these option grants, which was included in accrued expenses as of December 31, 2013.
	In February 2014, we entered into an agreement for method development by a contract manufacturer and issued an aggregate of 91,334 shares of common stock, valued at approximately $127,000, as compensation.
	In February 2014, we entered into an agreement to grant an aggregate of 47,800 shares of common stock to a consultant, which shares vest at the rate of 7,800 shares upon execution of the agreement and 10,000 shares per month for four months, the term of the agreement. These shares will be granted for business advisory services to be provided to the Company. In addition, the consultant was issued a warrant to purchase 96,000 shares of common stock at a strike price of $3.00 per share, which shares vest at the rate of 16,000 shares upon execution of the agreement and 20,000 shares per month for four months. The warrant issued is substantially similar to the warrants issued in conjunction with our financing completed in March 2013.

SUMMARY_OF_CRITICAL_ACCOUNTING1

SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Policies)

3 Months Ended

12 Months Ended

Mar. 31, 2014

Dec. 31, 2013

Accounting Policies [Abstract]

'

'

Use of Estimates, Policy [Policy Text Block]

'

'

Use of estimates

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying disclosures. Actual results may differ from those estimates.

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying disclosures. Significant estimates include the fair value of derivative instruments, stock-based compensation, recognition of clinical trial costs and other accrued liabilities. Actual results may differ from those estimates.

Research and Development Expense, Policy [Policy Text Block]

'

'

Research and Development

Research and Development

Research and development costs are charged to expense as incurred. Our research and development expenses consist primarily of expenditures for manufacturing, clinical trials, employee compensation and consulting costs and expenses.

Research and development costs are charged to expense as incurred. Our research and development expenses consist primarily of expenditures for toxicology and other studies, manufacturing, clinical trials, compensation and consulting costs.

We incurred research and development expenses of approximately $1.1 million, $0.8 million and $17.9 million for the three months ended March 31, 2014 and 2013, and from November 21, 2003 (inception) through March 31, 2014, respectively.

We incurred research and development expenses of $2.7 million, $2.9 million and $16.7 million for the years ended December 31, 2013 and 2012, and from November 21, 2003 (inception) through December 31, 2013, respectively.

Cash and Cash Equivalents, Policy [Policy Text Block]

'

'

Cash Equivalents

For purposes of the statements of cash flows, we consider all highly liquid debt instruments purchased with a maturity date of three months or less to be cash equivalents. We maintain our cash in bank deposit accounts which, at times, may exceed applicable government mandate insurance limits. We have not experienced any losses in our accounts

Concentration Risk, Credit Risk, Policy [Policy Text Block]

'

'

Concentrations of Credit Risk

Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments with credit quality institutions. At times, such investments may exceed applicable government mandated insurance limits. Cash and cash equivalents were $3.6 million and $2.3 million at December 31, 2013 and 2012, respectively.

We currently outsource all manufacturing of our clinical supplies to single source manufactures. We also have a single source supplier for the active ingredient in our prodrug compounds, including G-202. A change in these suppliers could cause a delay in manufacturing and/or clinical trials, which would adversely affect our Company

Goodwill and Intangible Assets, Policy [Policy Text Block]

'

'

Intangible Assets

Intangible assets consist of licensed technology, patents, and patent applications (see Note 5). The assets associated with licensed technology are recorded at cost and are being amortized on the straight line basis over their estimated useful lives of twelve to seventeen years

Property, Plant and Equipment, Policy [Policy Text Block]

'

'

Office Equipment

Office equipment is stated at cost less accumulated depreciation.  Depreciation is calculated on the straight line basis over the estimated useful lives of the assets of three to five years.  Expenditures for repair and maintenance which do not materially extend the useful lives of property and equipment are charged to expense. When property or equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are removed from the respective accounts with the resulting gain or loss reflected in operations. Management periodically reviews the carrying value of its office equipment for impairment.

Depreciation expense was approximately $6,000 and $4,000 for the years ended December 31, 2013 and 2012, respectively

Earnings Per Share, Policy [Policy Text Block]

'

'

Loss per Share

Loss per Share

Basic loss per share is calculated by dividing net loss and net loss attributable to common shareholders by the weighted average number of common shares outstanding for the period. Basic and diluted loss per share are the same, in that any potential common stock equivalents would have the effect of being anti-dilutive in the computation of net loss per share. The following potentially dilutive securities have been excluded from the computations of weighted average shares outstanding as of March 31, 2014 and 2013, as they would be anti-dilutive:

Basic loss per share is calculated by dividing net loss and net loss attributable to common shareholders by the weighted average number of common shares outstanding for the period. Basic and diluted loss per share are the same, in that any potential common stock equivalents would have the effect of being anti-dilutive in the computation of net loss per share.

Three months ended March 31,

The following potentially dilutive securities have been excluded from the computations of weighted average shares outstanding as of December 31, 2013 and 2012, as they would be anti-dilutive:

2014

2013

Shares underlying options outstanding

8,334,895

6,023,641

Year Ended December 31,

Shares underlying warrants outstanding

10,001,591

8,171,088

2013

2012

Shares underlying convertible notes outstanding

263,695

254,873

Shares underlying options outstanding

6,050,623

4,674,628

18,600,181

14,449,602

Shares underlying warrants outstanding

10,216,597

8,513,984

Shares underlying convertible notes outstanding

261,519

252,698

16,528,739

13,441,310

Fair Value of Financial Instruments, Policy [Policy Text Block]

'

'

Fair Value of Financial Instruments

Fair Value of Financial Instruments

Our short-term financial instruments, including cash, accounts payable and other liabilities, consist primarily of instruments without extended maturities. We believe that the fair values of our current assets and current liabilities approximate their reported carrying amounts.

Our short-term financial instruments, including cash, accounts payable and other liabilities, consist primarily of instruments without extended maturities. We believe that the fair values of our current assets and current liabilities approximate their reported carrying amounts.

Warrant derivative liability consists of certain of our warrants with anti-dilution provisions. We use the Black-Scholes option-pricing model to value our warrant derivative liability which incorporates our stock price, volatility, U.S. risk-free interest rate, dividend rate, and estimated life.

Warrant derivative liability consists of certain of our warrants with anti-dilution provisions. The Company uses the Black-Scholes option-pricing model to value its warrant derivative liability which incorporate the Company’s stock price, volatility, U.S. risk-free interest rate, dividend rate, and estimated life.

Fair Value Measurement, Policy [Policy Text Block]

'

'

Fair Value Measurements

Fair Value Measurements

Valuation Hierarchy - GAAP establishes a valuation hierarchy for disclosure of the inputs to valuation used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows:

The U.S. GAAP Valuation Hierarchy establishes a valuation hierarchy for disclosure of the inputs to valuation used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on our own assumptions used to measure assets and liabilities at fair value. A financial asset or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement.

Level 1:

Quoted prices (unadjusted) in active markets for identical assets or liabilities.

The Company previously had recorded a warrant derivative liability for warrants with anti-dilution provisions, which all the respective warrants were either exercised or expired as of December 31, 2013. The table below summarizes the fair values of our financial liabilities as of December 31, 2012 (in thousands):

Level 2:

Quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument.

Level 3:

Unobservable inputs based on our own assumptions used to measure assets and liabilities at fair value.

Fair Value at

December 31,

Fair Value Measurement Using

A financial asset or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. We previously recorded a warrant derivative liability for warrants with non-standard anti-dilution provisions. These warrants were either exercised or expired as of March 31, 2014.

2012

Level 1

Level 2

Level 3

Warrant derivative liability

$

1,176

$

—

$

—

$

1,176

The reconciliation of the warrant derivative liability measured at fair value on a recurring basis using unobservable inputs (Level 3) is as follows (in thousands):

2013

2012

Balance at beginning of year

$

1,176

$

1,734

Loss (gain) on change in fair value of warrant liability

-1,096

50

Reclassification to equity upon exercise of warrants

-80

-608

Balance at end of year

$

—

$

1,176

Income Tax, Policy [Policy Text Block]

'

'

Income Taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income and the reversal of deferred tax liabilities during the period in which the related temporary difference becomes deductible

Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]

'

'

Stock-Based Compensation

Stock-Based Compensation

We measure the cost of employee services received in exchange for equity awards based on the grant-date fair value of the awards. All awards under our stock-based compensation programs are accounted for at fair value and that cost is recognized over the period during which an employee is required to provide service in exchange for the award (the vesting period).

The Company measures the cost of employee services received in exchange for an equity award based on the grant-date fair value of the award. All grants under our stock-based compensation programs are accounted for at fair value and that cost is recognized over the period during which an employee is required to provide service in exchange for the award (the vesting period).

Compensation expense for options granted to non-employees is determined in accordance with the standard as the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measured. Compensation expense for awards granted to non-employees is re-measured each accounting period.

Compensation expense for options granted to non-employees is determined in accordance with the standard as the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measured. Compensation expense for awards granted to non-employees is re-measured each period.

Determining the appropriate fair value of the stock-based compensation requires the input of subjective assumptions, including the expected life of the stock-based compensation and stock price volatility. We use the Black-Scholes option-pricing model to value our stock option awards which incorporates our stock price, volatility, U.S. risk-free interest rate, dividend rate, and estimated life.

Determining the appropriate fair value of the stock-based compensation requires the input of subjective assumptions, including the expected life of the stock-based payment and stock price volatility.  The Company uses the Black-Scholes option-pricing model to value its stock option awards which incorporate the Company’s stock price, volatility, U.S. risk-free rate, dividend rate, and estimated life

Reclassification, Policy [Policy Text Block]

'

'

Reclassifications

Certain prior year balances have been reclassified to conform to current year presentation

New Accounting Pronouncements, Policy [Policy Text Block]

'

'

Recent Accounting Pronouncements

Recent Accounting Pronouncements

Recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the AICPA, and the SEC, did not, or are not believed by management, to have a material impact on the Company’s present or future financial statements.

Recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the AICPA, and the SEC, did not, or are not believed by management, to have a material impact on the Company's present or future financial statements

SUMMARY_OF_CRITICAL_ACCOUNTING2

SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Tables)	3 Months Ended				12 Months Ended
	Mar. 31, 2014				Dec. 31, 2013
Accounting Policies [Abstract]	'				'
Schedule of Weighted Average Number of Shares [Table Text Block]	'				'
	The following potentially dilutive securities have been excluded from the computations of weighted average shares outstanding as of March 31, 2014 and 2013, as they would be anti-dilutive:				The following potentially dilutive securities have been excluded from the computations of weighted average shares outstanding as of December 31, 2013 and 2012, as they would be anti-dilutive:
		Three months ended March 31,				Year Ended December 31,
		2014		2013		2013		2012
	Shares underlying options outstanding		8,334,895	6,023,641	Shares underlying options outstanding		6,050,623		4,674,628
	Shares underlying warrants outstanding		10,001,591	8,171,088	Shares underlying warrants outstanding		10,216,597		8,513,984
	Shares underlying convertible notes outstanding		263,695	254,873	Shares underlying convertible notes outstanding		261,519		252,698
			18,600,181	14,449,602			16,528,739		13,441,310
Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]	'				'
					The table below summarizes the fair values of our financial liabilities as of December 31, 2012 (in thousands):
						Fair Value at
						December 31,		Fair Value Measurement Using
						2012		Level 1		Level 2		Level 3
					Warrant derivative liability	$	1,176	$	—	$	—	$	1,176
Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings [Table Text Block]	'				'
					The reconciliation of the warrant derivative liability measured at fair value on a recurring basis using unobservable inputs (Level 3) is as follows (in thousands):
						2013		2012
					Balance at beginning of year	$	1,176	$	1,734
					Loss (gain) on change in fair value of warrant liability		-1,096		50
					Reclassification to equity upon exercise of warrants		-80		-608
					Balance at end of year	$	—	$	1,176

SUPPLEMENTAL_CASH_FLOW_INFORMA1

SUPPLEMENTAL CASH FLOW INFORMATION (Tables)	3 Months Ended					12 Months Ended
	Mar. 31, 2014					Dec. 31, 2013
Supplemental Cash Flow Information [Abstract]	'					'
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]	'					'
	The following table contains additional information for the periods reported (in thousands):					The following table contains additional information for the periods reported (in thousands).
		Three months ended March 31,					Year Ended December 31,
		2014		2013			2013		2012
	Non-cash financial activities:					Non-cash financial activities:
	Common stock options issued as payment of accrued compensation	$	962	$	999	Common stock options issued as payment of accrued compensation	$	999	$	674
	Derivative liability reclassified to equity upon exercise of warrants		–		15	Derivative liability reclassified to equity upon exercise of warrants		80		608

ACCRUED_EXPENSES_Tables

ACCRUED EXPENSES (Tables)	3 Months Ended					12 Months Ended
	Mar. 31, 2014					Dec. 31, 2013
Accrued Liabilities, Current [Abstract]	'					'
Schedule of Accrued Liabilities [Table Text Block]	'					'
	Accrued expenses consist of the following (in thousands):					Accrued expenses consist of the following (in thousands):
		March 31,		December 31,			December 31,
		2014		2013			2013		2012
	Accrued compensation and benefits	$	318	$	1,040	Accrued compensation and benefits	$	1,040	$	958
	Accrued research and development		190		82	Accrued research and development		82		100
	Accrued other		254		128	Accrued other		128		234
	Total accrued expenses	$	762	$	1,250	Total accrued expenses	$	1,250	$	1,292

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	'
	The following table summarizes future minimum lease payments as of December 31, 2013 (in thousands):
	2014	$	56
	2015		45
	Thereafter		–
	Total minimum lease payments	$	101
Restructuring and Related Costs [Table Text Block]	'
	As part of the agreements, the executives potentially shall be entitled to the following (in thousands):
		Chief		Chief
		Executive		Operating
		Officer		Officer
	Terminated without cause	$	1,727	$	909
	Terminated, change of control without good reason		1,727		—
	Terminated for cause, death, disability and by executive without good reason		363		309

STOCK_OPTIONS_Tables

STOCK OPTIONS (Tables)	3 Months Ended								12 Months Ended
	Mar. 31, 2014								Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'								'
Schedule of Stock-based Compensation Expenses for Stock Options and Warrants Issued [Table Text Block]	'								'
									Total stock-based compensation expense recognized for stock options issued using the straight-line method in the statement of losses for the year ended December 31, 2013 and 2012 is as follows (in thousands):
										2013			2012
									Stock-based compensation expense for employees and non-employee directors	$	1,140		$	322
									Equity awards for nonemployees issued for services		114			191
									Total stock-based compensation expense	$	1,254		$	513
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'								'
	The following table summarizes stock option activity under the Plans:								The following table summarizes stock option activity under the Plans:
		Number of		Weighted-		Weighted-average	Aggregate								Weighted-
		shares		Average		Remaining	Intrinsic					Weighted-			average	Aggregate
				Exercise		contractual term	value (in					average			remaining	intrinsic
				price		(in years)	thousands)			Number of		exercise			contractual term	value (in
	Outstanding at December 31, 2013	6,050,623		$	1.82					shares		price			(in years)	thousands)
	Granted	2,284,272		$	1.36				Outstanding at December 31, 2011	3,646,870		$	1.6
	Exercised	—			—				Granted	1,097,758		$	2.33
	Forfeited	—			—				Exercised	-70,000		$	0.5
	Outstanding at March 31, 2014	8,334,895		$	1.7	4.5	$	283	Forfeited	—			—
	Exercisable at March 31, 2014	8,132,015		$	1.7	4.5	$	280	Outstanding at December 31, 2012	4,674,628		$	1.79
									Granted	1,515,995		$	2.02
									Exercised	–		$	–
									Forfeited	-140,000		$	2.8
									Outstanding at December 31, 2013	6,050,623		$	1.82		4	$	272
									Exercisable at December 31, 2013	5,952,726		$	1.83		4	$	269
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	'								'
	The following table summarizes weighted-average assumptions using the Black-Scholes option-pricing model used on the date of the grants issued during the three months ended March 31, 2014 and 2013:								The following table summarizes weighted-average assumptions using the Black-Scholes option-pricing model used on the date of the grants issued for the years ended December 31, 2013 and 2012:
		Three months ended March 31,
		2014		2013						Year Ended December 31,
	Volatility	56	%	59.1	%					2013		2012
	Expected term (years)	3.4		3.6					Volatility	58.8	%	71.9	%
	Risk-free interest rate	0.5	%	0.5	%				Expected term (years)	3.7		2.8
	Dividend yield	0	%	0	%				Risk-free interest rate	0.6	%	0.3	%
									Dividend yield	None		None

WARRANTS_AND_DERIVATIVE_WARRAN1

WARRANTS AND DERIVATIVE WARRANT LIABILITY (Tables)	3 Months Ended								12 Months Ended
	Mar. 31, 2014								Dec. 31, 2013
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'								'
Schedule of Share-based Compensation, Activity [Table Text Block]	'								'
	Transactions involving our equity-classified warrants are summarized as follows:								Transactions involving our equity-classified and liability-classified stock warrants are summarized as follows:
		Number of		Weighted-		Weighted-average	Aggregate							Weighted-
		shares		Average		Remaining	Intrinsic					Weighted-		average	Aggregate
				Exercise		contractual term	value (in					average		remaining	intrinsic
				price		(in years)	thousands)			Number of		exercise		contractual term	value (in
	Outstanding at December 31, 2013	10,216,597		$	2.56					shares		price		(in years)	thousands)
	Granted	96,000		$	3
	Exercised	—			—				Outstanding at December 31, 2011	8,715,289		$	2.39
	Forfeited	-311,006		$	2.71				Granted	314,366		$	2.97
	Outstanding at March 31, 2014	10,001,591		$	2.56	2.8	$	48	Exercised	-515,671		$	1.52
									Forfeited	—			—
	Exercisable at March 31, 2014	10,001,591		$	2.56	2.8	$	48
									Outstanding at December 31, 2012	8,513,984		$	2.47
									Granted	4,376,228		$	1.97
									Exercised	-1,325,670		$	1.06
									Forfeited	-1,347,945		$	1.52
									Outstanding at December 31, 2013	10,216,597		$	2.56	2.9	$	48
									Exercisable at December 31, 2013	10,216,597		$	2.56	2.9	$	48
Schedule of Outstanding Warrants to Purchase Common Stock [Table Text Block]	'								'
	The following table summarizes outstanding common stock purchase warrants as of March 31, 2014:								The following table summarizes outstanding warrants to purchase common stock as of December 31, 2013:
		Number of		Weighted-		Expiration						Weighted
		shares		average								Average
				exercise						Number of		Exercise
				price						shares		price		Expiration
	Equity–classified warrants								Equity–classified warrants
	Issued to consultants	1,163,759		$	2.36	July 2014 through February 2019			Issued to consultants	1,128,759		$	2.28	February 2014 through January 2018
	Issued pursuant to 2009 financings	1,205,510		$	3	June 2014 through September 2014			Issued pursuant to 2009 financings	1,455,516		$	3	February 2014 through September 2014
	Issued pursuant to 2010 financings	1,022,943		$	3.38	January 2015 through May 2015			Issued pursuant to 2010 financings	1,022,943		$	3.38	January 2015 through May 2015
	Issued pursuant to 2011 financings	1,936,785		$	3.24	January 2016 through April 2016			Issued pursuant to 2011 financings	1,936,785		$	3.24	January 2016 through April 2016
	Issued pursuant to 2012 financings	296,366		$	3	Dec-17			Issued pursuant to 2012 financings	296,366		$	3	Dec-17
	Issued pursuant to 2013 financings	4,376,228		$	1.97	December 2017 through August 2023			Issued pursuant to 2013 financings	4,376,228		$	1.97	December 2017 through August 2023
		10,001,591								10,216,597
Schedule Of Share Based Payment Award Warrants Valuation Assumptions [Table Text Block]	'								'
									The following table summarizes weighted-average assumptions using the Black-Scholes option-pricing model used on the date of the equity-classified warrants issued for services for the year ended December 31, 2012:
									Volatility	60.3	%
									Expected term (years)	4.7
									Risk-free interest rate	0.7	%
									Dividend yield	None
Schedule of Share-based Payment Award, Warrants Derivative Liability Valuation Assumptions [Table Text Block]	'								'
	The following table summarizes the calculated aggregate fair values for the warrant derivative liability using the Black-Scholes method based on the following assumptions:								The following table summarizes the calculated aggregate fair values for the warrant derivative liability using the Black-Scholes method based on the following assumptions (in thousands):
		Fair value as of								Fair value as of
		March 31, 2013								December 31,
										2012
	Calculated aggregate value (in thousands)	$	1,010
	Exercise price per share of warrant	$	1.5						Calculated aggregate value	$	1,176
	Closing price per share of common stock	$	2.15						Exercise price per share of warrant	$	1.5
	Volatility		50	%					Closing price per share of common stock	$	2.2
	Expected term (years)		0.3						Volatility		54	%
	Risk-free interest rate		0.07	%					Expected term (years)		0.5
	Dividend yield		0	%					Risk-free interest rate		0.11	%
									Dividend yield		0	%

INCOME_TAXES_Tables

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	'
	Significant components of deferred tax assets and liabilities are as follows (in thousands):
		2013			2012
	Deferred tax assets:
	Net operating loss carryover	$	7,497		$	5,793
	Stock-based compensation		2,888			2,474
	Other		19			339
	Tax credits		398			374
	Total deferred tax assets		10,802			8,980
	Less: valuation allowance		-10,802			-8,980
	Net deferred tax assets	$	–		$	–
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	'
	The actual tax benefit differs from the expected tax benefit for the years ended December 31, 2013 and 2012 (computed by applying the U.S. Federal Corporate tax rate of 34% to income before taxes) are as follows:
		2013		2012
	Statutory federal income tax rate	-34	%	-34	%
	Non-deductible items	0.1	%	0	%
	Adjustment for R&D Credit	-0.4	%	-0.8	%
	Valuation allowance	34.4	%	34.8	%
	Effective income tax rate	–	%	–	%

MANAGEMENTS_PLANS_TO_CONTINUE_1

MANAGEMENT'S PLANS TO CONTINUE AS A GOING CONCERN (Details Textual) (USD $)	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Nov. 20, 2003
In Thousands, unless otherwise specified
Management Plan [Line Items]	'	'	'	'	'	'
Deficit accumulated during the development stage	$34,325	$32,385	'	$27,083	'	'
Cash and Cash Equivalents, at Carrying Value	$2,576	$3,587	$2,553	$2,345	$5,530	$0
Percentage of Cash and Cash Equivalents in Total Assets	90.00%	92.00%	'	'	'	'

SUMMARY_OF_CRITICAL_ACCOUNTING3

SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Details)	3 Months Ended		12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013	Dec. 31, 2012
Summary Of Critical Accounting Policies [Line Items]	'	'	'	'
Shares underlying, outstanding	18,600,181	14,449,602	16,528,739	13,441,310
Employee Stock Option [Member]	'	'	'	'
Summary Of Critical Accounting Policies [Line Items]	'	'	'	'
Shares underlying, outstanding	8,334,895	6,023,641	6,050,623	4,674,628
Warrant [Member]	'	'	'	'
Summary Of Critical Accounting Policies [Line Items]	'	'	'	'
Shares underlying, outstanding	10,001,591	8,171,088	10,216,597	8,513,984
Convertible Notes Payable [Member]	'	'	'	'
Summary Of Critical Accounting Policies [Line Items]	'	'	'	'
Shares underlying, outstanding	263,695	254,873	261,519	252,698

SUMMARY_OF_CRITICAL_ACCOUNTING4

SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Details 1) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'
Warrant derivative liability	$0	$1,176,000	$1,734,000
Fair Value, Inputs, Level 1 [Member]	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'
Warrant derivative liability	'	0	'
Fair Value, Inputs, Level 2 [Member]	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'
Warrant derivative liability	'	0	'
Fair Value, Inputs, Level 3 [Member]	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'
Warrant derivative liability	'	$1,176,000	'

SUMMARY_OF_CRITICAL_ACCOUNTING5

SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Details 2) (USD $)	3 Months Ended		12 Months Ended		121 Months Ended	124 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Mar. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'	'	'	'
Balance at beginning of year	$0	$1,176	$1,176	$1,734	'	'
Loss (gain) on change in fair value of warrant liability	0	-235	-1,096	50	-86	-86
Reclassification to equity upon exercise of warrants	'	'	-80	-608	'	'
Balance at end of year	'	'	$0	$1,176	$0	'

SUMMARY_OF_CRITICAL_ACCOUNTING6

SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES (Details Textual) (USD $)	3 Months Ended		12 Months Ended		121 Months Ended	124 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Mar. 31, 2014	Dec. 31, 2011	Nov. 20, 2003
Summary Of Critical Accounting Policies [Line Items]	'	'	'	'	'	'	'	'
Research and Development Expense, Total	$1,104	$790	$2,733	$2,922	$16,712	$17,936	'	'
Cash and Cash Equivalents, at Carrying Value, Total	2,576	2,553	3,587	2,345	3,587	2,576	5,530	0
Depreciation, Total	'	'	$6,000	$4,000	'	'	'	'
Maximum [Member]	'	'	'	'	'	'	'	'
Summary Of Critical Accounting Policies [Line Items]	'	'	'	'	'	'	'	'
Finite-Lived Intangible Asset, Useful Life	'	'	'17 years	'	'	'	'	'
Property, Plant and Equipment, Useful Life	'	'	'5 years	'	'	'	'	'
Minimum [Member]	'	'	'	'	'	'	'	'
Summary Of Critical Accounting Policies [Line Items]	'	'	'	'	'	'	'	'
Finite-Lived Intangible Asset, Useful Life	'	'	'12 years	'	'	'	'	'
Property, Plant and Equipment, Useful Life	'	'	'3 years	'	'	'	'	'

SUPPLEMENTAL_CASH_FLOW_INFORMA2

SUPPLEMENTAL CASH FLOW INFORMATION (Details) (USD $)	3 Months Ended		12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2010
Non-cash financial activities:	'	'	'	'	'
Common stock options issued as payment of accrued compensation	$962	$999	$999	$674	'
Derivative liability reclassified to equity upon exercise of warrants	$0	$15	$80	$608	$86

INTELLECTUAL_PROPERTY_Details_

INTELLECTUAL PROPERTY (Details Textual) (USD $)	3 Months Ended		12 Months Ended		48 Months Ended	121 Months Ended	124 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013	Mar. 31, 2014
Intellectual Property [Line Items]	'	'	'	'	'	'	'
Amortization of Intangible Assets	'	'	$17,000	$17,000	'	'	'
Payments To Acquire Intangible Assets	0	0	0	0	212,000	194,000	194,000
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months	'	'	17,000	'	'	17,000	'
Finite-Lived Intangible Assets, Amortization Expense, Year Two	'	'	17,000	'	'	17,000	'
Finite-Lived Intangible Assets, Amortization Expense, Year Three	'	'	17,000	'	'	17,000	'
Finite-Lived Intangible Assets, Amortization Expense, Year Four	'	'	17,000	'	'	17,000	'
Finite-Lived Intangible Assets, Amortization Expense, Year Five	'	'	$17,000	'	'	$17,000	'

ACCRUED_EXPENSES_Details

ACCRUED EXPENSES (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Accrued Expenses [Line Items]	'	'	'
Accrued compensation and benefits	$318	$1,040	$958
Accrued research and development	190	82	100
Accrued other	254	128	234
Total accrued expenses	$762	$1,250	$1,292

CONVERTIBLE_NOTES_PAYABLE_Deta

CONVERTIBLE NOTES PAYABLE (Details Textual) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Debt Instrument [Line Items]	'	'	'
Long-term Debt, Gross	$100,000	$100,000	'
Debt Instrument, Interest Rate, Effective Percentage	4.20%	4.20%	'
Debt Instrument, Maturity Date	6-Dec-11	6-Dec-11	'
Debt Instrument, Increase, Accrued Interest	27,000	26,000	21,000
Debt Instrument, Convertible, Conversion Price	$0.50	$0.50	'
Chief Executive Officer [Member]	'	'	'
Debt Instrument [Line Items]	'	'	'
Convertible Notes Payable, Total	$200,000	$200,000	'

COMMITMENTS_AND_CONTINGENCIES_1

COMMITMENTS AND CONTINGENCIES (Details) (USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified
Future Minimum Rental Payments For Operating Leases [Line Items]	'
2014	$56
2015	45
Thereafter	0
Total minimum lease payments	$101

COMMITMENTS_AND_CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Details 1) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013
Chief Executive Officer [Member] | Terminated without cause [Member]	'
Restructuring Cost and Reserve [Line Items]	'
Severance Provision And Indemnification Charges	$1,727
Chief Executive Officer [Member] | Terminated, change of control without good reason [Member]	'
Restructuring Cost and Reserve [Line Items]	'
Severance Provision And Indemnification Charges	1,727
Chief Executive Officer [Member] | Terminated for cause, death, disability and by executive without good reason [Member]	'
Restructuring Cost and Reserve [Line Items]	'
Severance Provision And Indemnification Charges	363
Chief Operating Officer [Member] | Terminated without cause [Member]	'
Restructuring Cost and Reserve [Line Items]	'
Severance Provision And Indemnification Charges	909
Chief Operating Officer [Member] | Terminated, change of control without good reason [Member]	'
Restructuring Cost and Reserve [Line Items]	'
Severance Provision And Indemnification Charges	0
Chief Operating Officer [Member] | Terminated for cause, death, disability and by executive without good reason [Member]	'
Restructuring Cost and Reserve [Line Items]	'
Severance Provision And Indemnification Charges	$309

COMMITMENTS_AND_CONTINGENCIES_3

COMMITMENTS AND CONTINGENCIES (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Commitments And Contingencies [Line Items]	'	'
Operating Leases, Rent Expense	$55,000	$26,000
Lease Expiration Date	14-Oct-15	'

CAPITAL_STOCK_AND_STOCKHOLDERS1

CAPITAL STOCK AND STOCKHOLDER'S EQUITY (Details Textual) (USD $)

1 Months Ended

3 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

Mar. 31, 2013

Jan. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2009

Dec. 31, 2008

Dec. 31, 2007

Aug. 31, 2013

Mar. 31, 2013

Jan. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Mar. 31, 2013

Equity Financing [Member]

Equity Financing [Member]

Equity Financing [Member]

Equity Financing [Member]

Equity Financing [Member]

Equity Financing [Member]

Maximum [Member]

Class of Stock [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants Exercised

'

'

'

119,100

537,722

37,301

'

'

'

'

'

'

'

'

'

Proceeds From Options and Warrant Exercises

'

'

'

$95,000

$404,000

$691,000

'

'

'

'

'

'

'

'

'

Warrants Exercised on Cashless Basis

'

'

1,000,000

537,722

1,000,000

78,333

'

'

'

'

'

'

'

'

'

Shares Issued During Period Upon Exercise of Warrants

'

'

'

537,722

325,670

537,722

'

'

'

5,000,032

'

'

'

'

'

Stock Issued During Period, Shares, Stock Options and Warrant Issued

'

'

'

'

325,670

544,639

'

'

'

'

557,256

104,095

'

'

'

Stock Issued During Period, Price Per Share Stock Options and Warrant

'

'

'

'

'

'

'

'

'

'

$1.77

$2.20

'

'

'

Proceeds From Issuance Common Stock and Warrants

'

'

'

'

'

'

'

'

'

'

1,000,000

200,000

'

'

'

Stock Issued During Period, Shares, New Issues

'

'

91,334

'

'

'

'

'

'

3,333,356

'

'

'

'

'

Stock Units Components, Description

'

'

'

'

'

'

'

'

'

'each unit consisting of (i) one share of the Companys common stock and (ii) one common stock purchase warrant.

'adjust the price per unit from $2.20 to $1.773

'

'

'Each unit consists of: (i) one share of common stock, and (ii) one common stock purchase warrant.

'

Stock Issued During Period New Issues Price Per Share

'

'

'

'

'

'

'

'

'

$1.50

'

'

'

'

'

Warrants Expiration Period

'

'

'

'

'6 months

'

'

'

'

'5 years

'

'

'

'5 years

'

Class of Warrant or Right, Exercise Price of Warrants

'

'

'

'

'

'

'

'

'

$1.75

$3

'

'

$3

'

Beneficially Interest, Percentage

'

'

'

'

'

'

'

'

'

4.99%

'

'

'

4.99%

'

Discretionary Increase, Percentage

'

'

'

'

'

'

'

'

'

9.99%

'

'

'

9.99%

'

Commission Percentage On Gross Proceeds

'

'

8.00%

'

'

'

'

'

'

8.00%

'

'

2.00%

'

'

Payments for Commissions

'

'

'

'

'

'

'

'

'

400,003

'

'

'

'

'

Non Accountable Expense to Placement Agent

'

'

'

'

'

'

'

'

'

100,001

'

'

'

'

'

Warrant percentage to Common Stock

'

'

8.00%

'

'

'

'

'

'

8.00%

'

'

'

'

'

Warrants to Purchase of Common Stock

'

'

'

'

'

'

'

'

'

266,668

'

'

'

'

'

Legal And Due Diligence Cost

'

'

'

'

'

'

'

'

'

35,000

'

'

'

'

'

Additional Placement Agent Fees

'

'

'

'

'

'

'

'

'

'(i) a cash fee of 4% of gross proceeds received from the exercise of the warrants, and (ii) additional transaction fees equal to 8% of gross proceeds and 8% warrant coverage for any future investment by one of the investors in the Company for a period of 12 months following the closing of the offering.

'

'

'

'

'

Placement Agent and Finders Fees Incurred

'

'

'

'

'

'

'

'

'

'

37,000

'

'

'

'

Common Stock Purchase Warrants Issued Shares

686,420

686,420

'

'

'

'

'

'

'

'

18,410

'

'

'

'

Stock Issued During Period Shares Adjust Price Per Unit

'

'

'

'

'

'

'

'

'

'

96,443

'

'

'

'

Partial Liquidated Damages Fee, Percentage

'

'

'

'

'

'

'

'

'

1.50%

0.50%

'

'

'

6.00%

Stock Issued During Period, Value, New Issues

'

'

127,000

'

'

'

104,000

2,320,000

650,000

'

'

'

'

'

'

Stock Issued During Period, Shares, Issued for Services

'

'

47,800

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Value, Issued for Services

'

'

$67,000

'

'

'

'

'

'

'

'

'

'

'

'

STOCK_OPTIONS_Details

STOCK OPTIONS (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Stock-based compensation expense for employees and non-employee directors	$1,140	$322
Equity awards for nonemployees issued for services	114	191
Total stock-based compensation expense	$1,254	$513

STOCK_OPTIONS_Details_1

STOCK OPTIONS (Details 1) (USD $)	3 Months Ended	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Number of shares, Outstanding at beginning of period (in shares)	6,050,623	4,674,628	3,646,870
Number of shares, Granted (in shares)	2,284,272	1,515,995	1,097,758
Number of shares, Exercised (in shares)	0	0	-70,000
Number of shares, Forfeited (in shares)	0	-140,000	0
Number of shares, Outstanding at end of period (in shares)	8,334,895	6,050,623	4,674,628
Number of shares, Exercisable at December 31, 2013 (in shares)	8,132,015	5,952,726	'
Weighted-average exercise price, Outstanding at beginning of period (in dollars per share)	$1.82	$1.79	$1.60
Weighted-average exercise price, Granted (in dollars per share)	$1.36	$2.02	$2.33
Weighted-average exercise price, Exercised (in dollars per share)	$0	$0	$0.50
Weighted-average exercise price, Forfeited (in dollars per share)	$0	$2.80	$0
Weighted-average exercise price, Outstanding at end of period (in dollars per share)	$1.70	$1.82	$1.79
Weighted-average exercise price, Exercisable at December 31, 2013 (in dollars per share)	$1.70	$1.83	'
Weighted-average remaining contractual term, Outstanding at December 31, 2013	'4 years 6 months	'4 years	'
Weighted-average remaining contractual term, Exercisable at December 31, 2013	'4 years 6 months	'4 years	'
Aggregate intrinsic value, Outstanding at December 31, 2013 (in dollars)	$283	$272	'
Aggregate intrinsic value, Exercisable at December 31, 2013 (in dollars)	$280	$269	'

STOCK_OPTIONS_Details_2

STOCK OPTIONS (Details 2)	3 Months Ended		12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Volatility	56.00%	59.10%	58.80%	71.90%
Expected term (years)	'3 years 4 months 24 days	'3 years 7 months 6 days	'3 years 8 months 12 days	'2 years 9 months 18 days
Risk-free interest rate	0.50%	0.50%	0.60%	0.30%
Dividend yield	0.00%	0.00%	0.00%	0.00%

STOCK_OPTIONS_Details_Textual

STOCK OPTIONS (Details Textual) (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Employee Service Share Based Compensation Non Vested Awards Weighted Average Period For Total Compensation Cost To Be Recognized	'	'	'6 months	'
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Stock Options	$100,000	'	$100,000	'
Share-based Compensation Arrangement, Options, Issued to Non Employee Directors	38,000	38,000	1,335,972	1,094,658
Share Based Compensation Arrangement Options Issued To Employees And Non Employee Directors Weighted Average Price	'	'	$0.84	$0.99
Share-based Compensation Arrangement, Options, Issued to Consultants	297,370	89,041	180,023	3,100
Share Based Compensation Arrangement Options Issued To Consultants Weighted Average Price	'	'	$0.75	$1.27
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	0	'	0	70,000
Proceeds from Stock Options Exercised	'	'	'	35,000
Share Based Compensation Arrangement Options Issued to Employee Directors	1,948,902	1,221,972	'	'
Allocated Share-based Compensation Expense, Total	1,069,000	1,077,000	'	'
Stock Granted, Value, Share-based Compensation, Gross	'	'	$962,000	$958,000
Plan 2009 [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	'	'	6,000,000	'
Share-based Compensation Arrangement by Share-based Payment Award, Shares Purchased for Award	'	'	2,996,972	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	'	'	3,003,028	'
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period	6,000,000	'	'	'
Plan 2007 [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	6,000,000	'	1,500,000	'
Share-based Compensation Arrangement by Share-based Payment Award, Shares Purchased for Award	'	'	3,363,651	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	'	'	2,776,349	'
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period	'	'	6,000,000	'
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights	'	'	'not less than 20% per year	'
Share Based Compensation Arrangement By Share Based Payment Award Vesting Period Description	'	'	'period of not more than five years	'
Share Based Compensation Arrangement By Share Based Payment Award Assumptions Expected Term 1	'	'	'10 years	'

WARRANTS_AND_DERIVATIVE_WARRAN2

WARRANTS AND DERIVATIVE WARRANT LIABILITY (Details) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Number of shares, Outstanding at beginning of period (in shares)	10,216,597	8,513,984	8,715,289
Number of shares, Granted (in shares)	96,000	4,376,228	314,366
Number of shares, Exercised (in shares)	0	-1,325,670	-515,671
Number of shares, Forfeited (in shares)	-311,006	-1,347,945	0
Number of shares, Outstanding at ending of period (in shares)	10,001,591	10,216,597	8,513,984
Number of shares, Exercisable at March 31, 2014 (in shares)	10,001,591	10,216,597	'
Weighted-average exercise price, Outstanding at beginning of period (in dollars per share)	$2.56	$2.47	$2.39
Weighted-average exercise price, Granted (in dollars per share)	$3	$1.97	$2.97
Weighted-average exercise price, Exercised (in dollars per share)	$0	$1.06	$1.52
Weighted-average exercise price, Forfeited (in dollars per share)	$2.71	$1.52	$0
Weighted-average exercise price, Outstanding at end of period (in dollars per share)	$2.56	$2.56	$2.47
Weighted-average exercise price, Exercisable at March 31, 2014 (in dollars per share)	$2.56	$2.56	'
Weighted-average remaining contractual term, Outstanding at March 31, 2014	'2 years 9 months 18 days	'2 years 10 months 24 days	'
Weighted-average remaining contractual term, Exercisable at March 31, 2014	'2 years 9 months 18 days	'2 years 10 months 24 days	'
Aggregate intrinsic value, Outstanding at March 31, 2014 (in dollars)	$48,000	$48,000	'
Aggregate intrinsic value, Exercisable at March 31, 2014 (in dollars)	$48,000	$48,000	'

WARRANTS_AND_DERIVATIVE_WARRAN3

WARRANTS AND DERIVATIVE WARRANT LIABILITY (Details 1) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Equity-classified warrants [Abstract]	'	'
Number of shares (in shares)	10,001,591	10,216,597
Consultant [Member]	'	'
Equity-classified warrants [Abstract]	'	'
Number of shares (in shares)	1,163,759	1,128,759
Weighted Average Exercise price (in dollars per share)	$2.36	$2.28
Expiration	'July 2014 through February 2019	'February 2014 through January 2018
Financing 2009 [Member]	'	'
Equity-classified warrants [Abstract]	'	'
Number of shares (in shares)	1,205,510	1,455,516
Weighted Average Exercise price (in dollars per share)	$3	$3
Expiration	'June 2014 through September 2014	'February 2014 through September 2014
Financing 2010 [Member]	'	'
Equity-classified warrants [Abstract]	'	'
Number of shares (in shares)	1,022,943	1,022,943
Weighted Average Exercise price (in dollars per share)	$3.38	$3.38
Expiration	'January 2015 through May 2015	'January 2015 through May 2015
Financing 2011 [Member]	'	'
Equity-classified warrants [Abstract]	'	'
Number of shares (in shares)	1,936,785	1,936,785
Weighted Average Exercise price (in dollars per share)	$3.24	$3.24
Expiration	'January 2016 through April 2016	'January 2016 through April 2016
Financing 2012 [Member]	'	'
Equity-classified warrants [Abstract]	'	'
Number of shares (in shares)	296,366	296,366
Weighted Average Exercise price (in dollars per share)	$3	$3
Expiration	'December 2017	'December 2017
Financing 2013 [Member]	'	'
Equity-classified warrants [Abstract]	'	'
Number of shares (in shares)	4,376,228	4,376,228
Weighted Average Exercise price (in dollars per share)	$1.97	$1.97
Expiration	'December 2017 through August 2023	'December 2017 through August 2023

WARRANTS_AND_DERIVATIVE_WARRAN4

WARRANTS AND DERIVATIVE WARRANT LIABILITY (Details 2)	12 Months Ended
	Dec. 31, 2012
Schedule Of Share Based Payment Award Warrants Valuation Assumptions [Line Items]	'
Volatility	60.30%
Expected term (years)	'4 years 8 months 12 days
Risk-free interest rate	0.70%
Dividend yield	0.00%

WARRANTS_AND_DERIVATIVE_WARRAN5

WARRANTS AND DERIVATIVE WARRANT LIABILITY (Details 3) (USD $)	3 Months Ended	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2012
Schedule Of Share Based Payment Award Warrants Derivative Liability Valuation Assumptions [Line Items]	'	'
Volatility	'	60.30%
Expected term (years)	'	'4 years 8 months 12 days
Risk-free interest rate	'	0.70%
Dividend yield	'	0.00%
Liability Classified Warrants [Member]	'	'
Schedule Of Share Based Payment Award Warrants Derivative Liability Valuation Assumptions [Line Items]	'	'
Calculated aggregate value (in thousands)	$1,010	$1,176
Exercise price per share of warrant	$1.50	$1.50
Closing price per share of common stock	$2.15	$2.20
Volatility	50.00%	54.00%
Expected term (years)	'3 months 18 days	'6 months
Risk-free interest rate	0.07%	0.11%
Dividend yield	0.00%	0.00%

WARRANTS_AND_DERIVATIVE_WARRAN6

WARRANTS AND DERIVATIVE WARRANT LIABILITY (Details Textual) (USD $)

1 Months Ended

3 Months Ended

12 Months Ended

1 Months Ended

3 Months Ended

12 Months Ended

Mar. 31, 2013

Jan. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Aug. 31, 2013

Jan. 31, 2013

Mar. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Equity Classified Warrants [Member]

Equity Classified Warrants [Member]

Equity Classified Warrants [Member]

Equity Classified Warrants [Member]

Liability Classified Warrants [Member]

Liability Classified Warrants [Member]

Warrants And Derivative Warrant Liability [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants Exercised

'

'

'

119,100

537,722

37,301

'

'

'

'

'

242,000

437,000

Proceeds from Warrant Exercises

'

'

'

$1,000,000

$404,000

$700,000

'

'

'

'

'

'

'

Warrants Exercised on Cashless Basis

'

'

1,000,000

537,722

1,000,000

78,333

'

'

'

'

'

'

'

Shares Issued During Period Upon Exercise of Warrants

'

'

'

537,722

325,670

537,722

'

'

'

'

'

'

'

Share-based Compensation Expense Recognized for Warrants Issued to Consultants

'

'

40,000

4,000

2,000

14,000

'

'

'

'

'

'

'

Common Stock Purchase Warrants Issued Shares

686,420

686,420

'

'

'

'

'

3,600,024

776,204

776,204

'

'

'

Share-based Compensation Arrangement, Warrants Issued to Placement Agent

'

'

'

'

'

'

'

266,668

'

18,410

18,410

'

'

Share-based Compensation Arrangement, Warrants Issued to Investors

'

'

'

'

'

'

'

3,333,356

'

71,374

71,374

'

'

Warrants Weighted Average Fair Value

'

'

$0.41

'

'

$1.31

'

$1.75

'

$3

$3

'

'

Derivative, Gain on Derivative

'

'

200,000

'

1,100,000

'

'

'

'

'

'

'

'

Derivative, Loss on Derivative

'

'

'

'

'

1,000,000

'

'

'

'

'

'

'

Share Based Compensation ArrangementWarrants Issued To Consultants (in Shares)

'

'

96,000

'

'

18,000

'

'

'

'

'

'

'

Derivative Liability

'

'

'

'

$0

$1,176,000

$1,734,000

'

'

'

'

$80,000

$608,000

INCOME_TAXES_Details

INCOME TAXES (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Deferred tax assets:	'	'
Net operating loss carryover	$7,497	$5,793
Stock-based compensation	2,888	2,474
Other	19	339
Tax credits	398	374
Total deferred tax assets	10,802	8,980
Less: valuation allowance	-10,802	-8,980
Net deferred tax assets	$0	$0

INCOME_TAXES_Details_1

INCOME TAXES (Details 1)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Schedule Of Effective Income Tax Rate Reconciliation [Line Items]	'	'
Statutory federal income tax rate	-34.00%	-34.00%
Non-deductible items	0.10%	0.00%
Adjustment for R&D Credit	-0.40%	-0.80%
Valuation allowance	34.40%	34.80%
Effective income tax rate	0.00%	0.00%

INCOME_TAXES_Details_Textual

INCOME TAXES (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Income Taxes [Line Items]	'	'
Operating Loss Carryforwards	$22,000,000	'
Operating Loss Carryforward Expiration Dates	'which will expire at various dates beginning in 2013 through 2024.	'
Deferred Tax Assets, Tax Credit Carryforwards, Total	398,000	374,000
Deferred Tax Assets Tax Credit Carryforwards Expiration Dates	'which will expire from 2028 through 2034.	'
Operating Loss Carryforwards Valuation Allowance Percentage	100.00%	'
Valuation Allowance, Deferred Tax Asset, Change in Amount	$1,700,000	$1,800,000
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	-34.00%	-34.00%

SUBSEQUENT_EVENTS_Details_Text

SUBSEQUENT EVENTS (Details Textual) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2009	Dec. 31, 2008	Dec. 31, 2007
Subsequent Event [Line Items]	'	'	'	'	'	'
Stock Issued During Period, Shares, New Issues	91,334	'	'	'	'	'
Stock Issued During Period, Value, New Issues	$127,000	'	'	$104,000	$2,320,000	$650,000
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross	2,284,272	1,515,995	1,097,758	'	'	'
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$1.36	$2.02	$2.33	'	'	'
Stock Granted, Value, Share-based Compensation, Gross	'	962,000	958,000	'	'	'
Subsequent Event [Member]	'	'	'	'	'	'
Subsequent Event [Line Items]	'	'	'	'	'	'
Stock Issued During Period, Shares, New Issues	'	91,334	'	'	'	'
Stock Issued During Period, Value, New Issues	'	127,000	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	'	'7 years	'	'	'	'
Stock Granted, Value, Share-based Compensation, Gross	'	$962,000	'	'	'	'
Warrants Issued To Purchase Common Stock	'	96,000	'	'	'	'
Warrant Exercise Price	'	$3	'	'	'	'
Subsequent Event [Member] | Executive Officer [Member]	'	'	'	'	'	'
Subsequent Event [Line Items]	'	'	'	'	'	'
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross	'	1,948,902	'	'	'	'
Subsequent Event [Member] | Consultant [Member]	'	'	'	'	'	'
Subsequent Event [Line Items]	'	'	'	'	'	'
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross	'	47,800	'	'	'	'
Subsequent Event [Member] | Common Stock One [Member]	'	'	'	'	'	'
Subsequent Event [Line Items]	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares	'	7,800	'	'	'	'
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares Per Month	'	10,000	'	'	'	'
Subsequent Event [Member] | Common Stock Two [Member]	'	'	'	'	'	'
Subsequent Event [Line Items]	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares	'	16,000	'	'	'	'
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares Per Month	'	20,000	'	'	'	'
Maximum [Member] | Subsequent Event [Member]	'	'	'	'	'	'
Subsequent Event [Line Items]	'	'	'	'	'	'
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	'	$1.42	'	'	'	'
Minimum [Member] | Subsequent Event [Member]	'	'	'	'	'	'
Subsequent Event [Line Items]	'	'	'	'	'	'
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	'	$1.29	'	'	'	'